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Abstract 
 
 
 
The main problem with influenza is the lack of broadly protective vaccines. In order to be 
prepared against an emerging pandemic, we need to generate vaccines that can address the 
diversity of the influenza virus. Influenza strains diverge by 1-2 % each year, due to the 
always ongoing antigenic drift and the occasional antigenic shifts. As a result, the annual 
influenza vaccines have to undergo frequent formulation changes, in order to elicit protection 
against the circulating influenza viruses. Thus, development of novel vaccines that can protect 
against circulating viral antigenic diversity is needed.  
 
This study describes the development and testing of two mosaic influenza antigens that were 
designed to confer broader protection against influenza. The mosaic antigens were inserted as 
antigenic units into previously described vaccine proteins designed to target antigens to 
different surface molecules on APCs. The mosaic genes were generated in silico using 
available hemagglutinin sequences collected from the ncbi database. One mosaic contained 
epitopes of the HA1 subtype only (HA1), while the other mosaic contained epitopes from all 
available subtypes of HA (HA1-17). The modified vaccine constructs were equipped with 
targeting units that would direct them to various receptors on APCs, such as chemokine 
receptors 1, 3 and 5, Xcr1, and MHC class II molecules. The ability of the vaccine constructs 
to mediate broad protection against influenza was tested by measuring the induction of cross-
reactive antibody and T cell responses. Furthermore, the ability to mediate protection against 
a lethal dose of different H1 influenza viruses was investigated by viral challenge.  
 
DNA immunization with vaccine plasmids encoding the mosaic antigens targeted towards 
various receptors on APC demonstrated induction of cross-subtype antibodies and antigen-
specific T cells. Both the APC-targeted HA1 and HA1-17 mosaic antigens could confer 
protection against a challenge with influenza H1N1.  The most interesting antigen in this 
respect is the HA1-17 mosaic, as this is more distantly related to HA from H1N1 influenza 
viruses.  
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1 Introduction  
 
 
Vaccines is seen as one of the greatest triumphs in the history of public health. Many major 
human diseases, like smallpox, polio and measles, have been brought under control by 
vaccination programs and focused surveillance of the diseases[1]. Still, other diseases are 
more difficult to prevent by vaccination. One of these diseases is caused by the influenza 
virus, which diverge by 1-2 % each year due to both minor and more major changes in its 
outer glycoproteins[2]. The resulting species variation creates the need for a novel vaccine 
that can meet these challenges.  
 
1.1 Influenza 
  
1.1.1 Disease burden 
 
Influenza is a contagious respiratory illness that mainly affects the nose, throat, bronchi, and 
occacionally the lungs. It is caused by the influenza virus, Myxovirus influenzae, that belongs 
to the Orthomyxoviridae family of RNA viruses with a viral envelope. People infected with 
the influenza virus will typically experience symptoms of the common cold, like severe 
aching, headaches, fatigue, and normally fever[3]. In addition, seasonal influenza has a 
significant economic impact on society, as it reduces productivity in both the work place and 
at home due to incapacitating illness, and because of the health-care costs associated with 
treatment. Normally, we recover from ”the flu” from within a few days to less than two 
weeks, but for parts of the population the disease can have more severe consequences. For the 
very young, the elderly and people with serious medical conditions, seasonal influenza 
associated complications claims thousands of lives every year. Annually, seasonal influenza  
has been estimated to cause 250 000 – 500 000 deaths worldwide, and to inflict 3-5 million 
cases of severe illness[4].  
 
In addition to the annual impact of seasonal influenza comes the potential social and 
economic burden of a pandemic influenza. With uneven intervals, reassortments between 
different strains of influenza may give rise to novel viruses against which the population has 
no prior immunity[5]. In such instances, an influenza pandemic may emerge. Although rare, 
the mortality rate associated with these large outbreaks can be striking, and even healthy 
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people might be at risk of complications[6]. The 1918-1919 influenza pandemic was the most 
devastating pandemic in modern history, claiming somewhere between 20 and 40 million 
lives. A disproportionate amount of the pandemic deaths was found in the young adult 
population[7]. In whatever part of the globe it struck, healthy young adults between 20 and 40 
years of age were most severily hit by the pandemic[7]. A possible explanation for this 
unusual age distribution is cytokine storms, that are a potentially fatal immune reaction 
consisting of a positive feedback loop between cytokines and white blood cells, leading to 
highly elevated levels of various cytokines[8]. Thus, a healthy immune system can under 
certain circumstances, such as pandemic influenza, become uncontrollably activated, and 
thereby cause significant damage to tissue and organs[8].   
 
1.1.2 Virus structure and hemagglutinin 
 
The influenza virion has a roughly spherical shape and is characterized by an external layer 
with hundreds of spike-like projections. This outer layer is composed of lipids obtained from 
the last host cell, when the newly made virions budded from its surface. Inside the envelope is 
a coat formed by viral matrix proteins that bind both the envelope and the viral RNA genome 
simultaneously[9]. Each of the eight negative sense RNA molecules (segments) of the 
genome is complementary to one mRNA, and one mRNA encodes either one or two of the 
viral proteins. Segment 1-3 encodes the proteins Polymerase B2, Polymerase PB1 and 
Polymerase PA, resepectively, which together make out the components of the virus’ RNA 
polymerase. Segment 5 encodes Nucleoprotein (NP), a structural protein that encapsidates the 
viral RNA. Segment 7 encodes the matrix protein M1, which make out the inner coat between 
the envelope and the RNA-nucleoprotein core, and M2, an ion-channel integral of the viral 
envelope. Segment 8 encodes the non-structural proteins NS1 and NS2, and lastly, segment 4 
and 6 encode the proteins hemagglutinin (HA) and neuraminidase (NA), respectively[9] (fig. 
1.1). Both of these proteins are embedded in the viral envelope, but they have opposite 
functions. NA mediates the release of newly formed virions after replication by cleaving sialic 
acid residues from glycoproteins or glycolipids. HA’s function is on the contrary to enable the 
virus to bind and fuse with target cells[10].   
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Figure 1.1. Schematic of an influenza A virus: The lipid envelope of the influenza virus is derived 
from the membrane of its host cell. The envelope proteins, HA, NA, and M2, are empedded in the 
lipid bilayer. HA and NA are the main surface glycoproteins of influenza A viruses. Figure reprinted 
from Subbarao (Subbarao 2007).  
 
The rod-shaped hemagglutinin molecule is the most abundant protein on the surface of 
influenza. It is a trimer made up of identical subunits, where each is made up of two 
polypeptides resulting from a cleaved precursor. The molecule has a conserved stem region 
where the amino acid composition hardly vary among different strains, and a globular head 
region with a greater variety[10]. Before cleaving of the precursor, hemagglutinin exists as 
one long polypeptide, HA0, which gives the virus the ability to contact and bind target cells. 
The contact is mediated between the receptor-binding site at the tip of the molecule and sialic 
acids that are part of glycoproteins or glycolipids on the surface of cells[11].  
 
When the influenza virus is bound to its target cell, hemagglutinin is cleaved into a state that 
activates its membrane fusion potential. The resulting polypeptides are called HA1 and HA2, 
and are held together by disulphide bonds[11]. The stem region of HA consists of parts of 
both HA1 and HA2, and contains a conserved stretch of 20 mostly hydrophobic residues at 
the N-terminus of HA2. This stretch is called the ”fusion peptide”, as it mediates the fusion 
process between the membrane of the virus and the membrane of the host cell[10]. Upon 
entry of influenza virus into lysosomes, the lowered pH will trigger a conformational change 
in hemagglutinin. This leads to exposure of the fusion peptide that was previously sequestered 
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in the interior of the structure, and removal of HA1 from the host cell membrane (fig. 
1.2)[12]. The fusion peptide will insert into and perturb the target membrane, before initiating 
formation of lipidic fusion intermediates. These intermediate ”stalks” will eventually lead to a 
hemifusion of the membranes that forms a fusion pore in the host cell membrane, enabling 
virus entrance[10].  
 
 
Figure 1.2. Conformational change of influenza HA structure at the pH of membrane fusion: The 
conformation of the HA monomer changes when entering an environment with a lower pH. The new 
positions of the carboxy- and amino termini of HA1 and HA2 (C1, N1, C2, and N2) make the fusion 
peptide at det N2 termini to ”pop” out from the interior of the structure. This enables the fusion 
peptide to move towards the host endosomal membrane, and leads eventually to a fusion of the 
membranes. Figure adapted from Steinhauer (Steinhauer 1996). 
 
The remaining part of HA1 makes out a globular domain at the tip of the hemagglutinin 
molecule, and three of these globular HA1 domains together make out the receptor-binding 
site. This part contains major antigenic epitopes which are targets for neutralizing 
antibodies[10]. As HA is also the most abundant protein on the cell surface, it is the primary 
target for a host cells immune response.  
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1.1.3 Influenza virus diversity  
 
A major concern with the influenza virus is the great variety of influenza strains. They can be  
divided into three main types, the A, B and C type viruses, that can all infect humans, but that 
lead to varying degree of disease[4]. Type A viruses are the group responsible for large 
pandemics, and are further classified into subtypes based on the genes encoding the surface 
proteins hemagglutinin and neuraminidase. Both A and B type viruses lead to seasonal 
influenza epidemics every year, although the B type normally cause a less severe disease than 
the A type[13]. B type viruses are found only in humans and therefore have a less exchange of 
genetic information with other viruses, and might explain why they dont cause pandemics. 
Fewer viruses lead to less variation and opportunities for recombination with other virus 
strains. The C type causes only a mild respiratory illness and does not lead to pandemics[13]. 
The variety of the surface protein genes of type A influenza, has classified hemagglutinin into 
18 different subtypes and neuraminidase into 11 different subtypes. The great number of 
possible gene combinations leads to a correspondingly large amount of different virus 
subtypes[13]. These subtypes are again divided into different virus strains, increasing the 
challenge of recognizing them with our immune system even further.    
 
The replication of the RNA genome of influenza is relatively error-prone, and provides 
natural selection with many point mutations to act on. This ability to change its genes over 
time, or antigenic drift, leads to small changes in influenza virus epitopes, making our 
immune system unable to recognize them. Additionally, more abrupt and major changes in 
the genome, called antigenic shifts, also contributes to the evolution of influenza[14]. 
Antigenic shifts can take place when reassortment of genes from different viruses lead to 
generation of novel viruses. A lack of immunity against these viruses in the population, gives 
them the potential to cause pandemics. The H1N1/09 flu pandemic (swine flu) was caused by 
a new strain of influenza A virus of H1N1 subtype. This strain is thought to be a reassortment 
between four known strains of the influenza A virus H1N1 subtype, where one of them is 
endemic in humans, one is endemic in birds, and two are endemic in pigs[15]. The lack of 
pre-existing antibody-mediated immunity among the human population made it possible for 
the reassorted virus to spread rapidly. Although an estimated 284 500 people were killed by 
the disease, the pandemic was fortunately not as severe as initially predicted[16].  
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Antigenic shifts can also cause pandemic influenza in the absence of reassortment. An 
example to this is the scenario of a non-human novel influenza virus gaining the ability to 
transmit among humans in a sustained and efficient manner. The current global situation is 
characterized by an increase in animal influenza viruses co-circulating, and thereby 
exchanging genetic material[17, 18]. Viruses of the H5 and H7 subtypes are at present of 
greatest concern, as they can rapidly mutate from a form that causes mild symptoms in birds 
into a form that causes severe illness and death in poultry populations, resulting in devastating 
outbreaks[19]. Also, the death rates reported when people are infected with them, are 
strikingly high. The fear is that these highly pathogenic viruses might mutate into a form that 
gains the ability to infect between people aswell[19]. 
 
 
1.1.4 Vaccination against influenza  
 
Vaccination is the principal mean by which the substantial health burden of seasonal 
influenza can be reduced[20]. It reduces the likelihood of becoming ill, and of transmitting the 
disease to others. The seasonal influenza vaccines are usually trivalent vaccines, protecting 
against two influenza A viruses (an H1N1 virus and an H3N2 virus) and an influenza B virus. 
Quadrivalent vaccines protecting against two influenza A viruses and two influenza B viruses 
are also available, although more rarely used. The most common type of vaccine is the 
inactivated influenza vaccines (IIVs), containing inactivated virus, and that is available in 
many different versions. This type of vaccine has been available since the 1940s and is 
typically administered intramuscularly. The live attenuated vaccines (LAIVs) became 
available in the 1960s, and is administered as a nasal spray. They contain live attenuated 
(weakened) influenza virus, meaning that the viruses are still capable of replication but are 
not virulent [21].  
 
The composition of both these influenza vaccines is based on the recommendations of the 
World Health Organization (WHO). The selection of viruses to be included is based on 
world-wide surveillance of influenza viruses circulating among humans, and is made almost a 
year ahead of the influenza season[22]. Despite all effort made to monitor the viruses, the 
match between viruses included in the vaccines and circulating viruses may vary 
significantly[23]. Even if they were to match, the ability of the influenza virus to continually 
undergo genetic changes (antigenic drift) leaves us with a vaccine that protects us for only a 
limited amount of time, and annual vaccination is therefore needed[24].  
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The currently available influenza vaccines are prepared by inoculating virus into chicken 
eggs. The fertilized hen’s eggs are incubated for several days to allow the viruses to replicate. 
Fluid harvested from the eggs will contain high titers of virus ready to be either killed 
(inactivated) or weakened before they are purified[25]. The amount of chicken eggs needed 
for production of a vaccine is enourmous. About 1-2 eggs is required for production of a 
single vaccine dose[26]. The process is also very time-consuming, and the time it will take to 
produce a novel vaccine will be almost a year. Another downside with this method, is the 
ability of influenza viruses to mutate into a form that is lethal to chicken embryos[26]. This 
could make it impossible to use eggs for production of vaccines against pandemic avian 
influenza viruses. Furthermore, the vaccines may not be suitable for people who are severely 
allergic (hypersensitive) to eggs, as there is a risk of allergic and anaphylactic reactions in 
response to them. For LAIVs, there is also a small risk that the attenuated virus may mutate 
and regain infectivity, possibly causing the disease instead of hindering it[27].  
 
1.2 The immune system 
 
 
The immune system is our defense against the numerous infectious organisms that our bodies 
are constantly exposed to. It comprises specialized organs, tissues and cells that all work 
together to prevent us from being infected[28]. This section will first address each of the two 
types of immunity, before the most important immune cells and their receptors are further 
described. Understanding how the immune system works is key to a successful vaccination 
that will generate a desired protection against influenza.  
 
1.2.1 Innate immunity 
The defenses of the innate immune system are activated immediately, or soon, after a 
pathogen is confronted. It is an ancient form of immunity which is genetically inherited and 
present in nearly all multicellular organisms[28]. The different elements of the system 
includes anatomical barriers, secretory molecules and cellular components[29].   
 
Anatomical barriers  
Only in rare cases does a pathogen succeed in penetrating the physical barriers of a body. The 
epithelial surfaces of the skin is impermeable to most invading pathogens and the mucosal 
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epithelium of the respiratory and gastrointestinal tract has a trapping effect[29]. Tears, saliva and 
nasal secretions contain chemical factors that can break down the cell walls of bacteria, and the pH 
of sweat will prevent them from growing[30]. However, tissue damage may occur, and an 
infection will follow as pathogens are able to penetrate the skin or mucosal surfaces.  
 
Secretory molecules 
A system of plasma proteins called the complement system is the second line of defense by the 
innate immune system. Its job is to complement immune cells in their work with clearing 
pathogens from the body, and performs this through a variety of antimicrobial functions[31]. 
Some specific complement proteins can by polymerization on cell surfaces lead to formation of 
pores in the membrane. This disrupts the lipid bilayer of the membrane and may lead to cell 
lysis[31]. Other complement proteins have proteolytic functions, and cleave antigens into peptides 
that signal the host cells to produce different chemical factors. The chemical factors, e.g. 
cytokines, will in turn enhance inflammation and immune responses to foreign antigens[31]. Other 
complement proteins have the ability to coat virions and thereby mark them for their destruction. 
Phagocytic cells with receptors for these coat proteins will be recruited to engulf and destroy the 
virus particles[31].  
 
Cellular barriers  
Macrophages are a type of myeloid cell that have the ability to phagocytose pathogens. They 
will engulf and digest foreign substances, microbes, cancer cells, and anything else that is not 
recognized as healthy body cells. In addition to phagocytosis, they are also capable of 
extracellular killing of infected self target cells[32]. Macrophages will recruit a different type 
of phagocytic cell, the neutrophils, that attack by completely surrounding the microorganism 
and digesting it with digestive enzymes[29]. Additionally, natural killer (NK) cells will 
migrate to the site of infection, and attack target cells by releasing cytotoxic proteins stored 
within secretory lysosomes[29]. Together, these cells make out the main line of defense of the 
non-specific immune system. All of them have germline-encoded pattern recognition 
receptors (PRRs) expressed on their surface. These receptors enable them, in an unspecific 
way, to recognize pathogen-associated molecular patterns (PAMPs), that are present on all 
pathogens. The patterns are made out of highly conserved molecules that pathogens share 
among them, but that host cells lack[33].  
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Lastly, the innate cells have a role in activation of the second type of immunity, mediated 
by the adaptive immune system. This takes place when macrophages degrade antigen into 
peptides and present them on their cell surface, leading to recruition of the lymphocyte 
cells responsible for adaptive immunity[32].  
 
1.2.2 Adaptive immunity 
The innate immune system is able to fight off the vast majority of invading microorganisms, 
but a second more specific immune response is needed for the ones that escape it. A system of 
lymphocyte cells make out the adaptive, or acquired, immune system, that is present in all 
vertebrates[28]. This system uses an entirely different strategy for pathogen recognition, 
where each different cell has its own specific type of cell-surface receptor. In contrast to the 
germline-encoded PRRs of the innate system, these receptors are acquired through contact 
with specific pathogens during our lifetime[34].  
 
The receptors can be made in an almost infinite number of versions due to genetic 
mechanisms that recombine the germline genes[35]. The result is a cell-surface receptor with 
a unique antigen specificity that enables a much stronger protection, which is important for 
keeping up with the rapidly evolving microorganisms[35]. After encountering their antigen, 
the lymphocytes proliferate to increase their numbers and undergo cellular differentiation to 
become effector cells[34]. The effector cells of adaptive immunity also mediate both a 
humoral response, like the secretory molecules of innate immunity, and a cell-mediated 
response, like the innate immune cells, against pathogens. The cells mediating the humoral 
response are called B lymphocytes, or B cells, whose function in the adaptive immune system 
is to secrete antibodies; a Y-shaped protein molecule used to identify and neutralize 
pathogens. The T lymphocytes, or T cells, play important roles in all arms of immunity and 
exist in two main types, the T helper cells and the cytotoxic T cells[34].  
 
In addtion a high specificity, the second advantage of adaptive immunity is the ability to 
create long-lasting protection[34]. Protection against a subsequent infection with the same 
pathogen is increased, due to a subset of B and T cells that have differentiated into memory 
B- and T cells. Upon re-exposure, the memory cells use their previous encounter with an 
antigen to beat it in a more effective way, preventing it from causing the disease. Because of 
this ability to ”learn”, we say the adaptive immune system has memory[35]. Immunological 
memory is used by vaccines in a similar way. Vaccines can induce an immune response 
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similar to that produced by a natural infection, without subjecting the recipient to the disease 
and its potential complications. The cells activated in response to vaccination can be retained 
long after the vaccine delivery.  
 
1.2.3 T cells  
T cells are a subset of lymphocyte cells defined by their development in the thymus and the T 
cell receptor (TCR) present on their cell surface. They migrate from their origin in the bone 
marrow for maturation and differentiation into various types of mature T cells in the 
thymus[36].   
 
The T cell receptor is a disulfide-linked membrane-anchored heterodimeric protein made up 
of two polypeptide chains, normally of type α and β, and expressed as part of a complex with 
invariant CD3 molecules. For some few T cells, the polypeptide chains are made of two other 
variant polypeptide chains, the γ and δ chain. Each of the chains has a constant region, 
proximal to the cell membrane, and a variable region able to make contact with foreign 
antigens (fig.1.3)[37]. The TCR recognizes antigens as peptides in complex with certain 
protein molecules on the surface of antigen-presenting cells (APCs). APCs are cells that are 
able to process and present antigens on their surface[37]. The proteins are MHC (major 
histocompatibility complex) molecules, whose function is to bind peptide fragments derived 
from pathogens and display them on the cell surface.   
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Figure 1.3. Overview of a T cell Receptor on the surface of a T cell: The TCR is a disulfide-linked 
membrane-anchored heterodimeric protein. It is composed of two different protein chains, normally 
the α and β chains, making out a heterodimer. Each chain consists of two extracellular domains; a 
constant (C) region and a variable (V) domain. The variable region of each polypeptide chain together 
make out the antigen-binding site. Copyright 2008 by Pearson Education, inc., publishing as Benjamin 
Cummings.      
 
 
Before encounter with foreign antigens and activation, T cells go through two selection 
processes. The first process, positive selection, selects for cells that are capable of recognizing 
foreign peptides complexed with MHC molecules. The cells remaining after this selection end 
up being eliminated by apoptosis[38].  The other process, called negative selection, selects for 
cells that do not bind self-peptides complexed with a self MHC protein. To prevent the 
immune system from attacking cells that are part of the body, the self-reactive cells are also 
destined to die by apoptosis[36].  
 
The T cells that have survived both selection processes, migrate to peripheral lymphoid 
organs where they are activated by APCs. The MHC molecules on these cells, presenting 
peptide antigens, interact simultaneously with the TCR and a co-receptor present on the T cell 
surface[37]. A complex of invariant transmembrane proteins (CD3) that is associated with the 
TCR, will transduce this binding of the peptide-MHC complex into intracellular signals. 
These will signal the cell nucleus to initiate transcription of genes needed for T-cell 
proliferation and differentiation into effector cells[38].  
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CD4 T cells  
CD4 positive T cells carry the co-receptor protein CD4 on their surface. They mature into a 
type of effector cell called T helper cells, which have a major role in controlling and 
regulating the immune system by providing ”help” to other white blood cells. They stimulate 
the immune responses of B cells, macrophages and cytotoxic T cells. However, they can only 
funtion after being activated themselves[36, 37].  
 
MHC molecules exist in two forms that differ in both structure and function, and the type of 
MHC molecule that interacts with a T cell will depend on the type of co-receptor present on 
it. T cells with a CD4 co-receptor interact only with the MHC class II molecules, that have the 
ability to present foreign antigens found in extracellular fluid. APCs that carry MHC class II 
molecules are either dendritic cells, macrophages or certain B cells, which are the three cell 
types called professional APCs. Some activated T helper cells are involved with helping B 
cells secrete antibodies and are called TH2 cells. The other group, the TH1 cells, help 
macrophages destroy ingested microbes, and also help activate cytotoxic T cells, enabling 
them to kill their infected target cells[37].    
 
CD8 T cells  
T cells with a CD8 co-receptor present on their surface will interact with the MHC class I 
molecules. These molecules present antigens that have been taken up and degraded by the 
MHC class I-expressing cell. These cells can be virtually all nucleated cells, giving the CD8 
positive T cells the possibility of interacting with a wide array of different cells. The CD8 
effector T cells are cytotoxic cells capable of killing cells infected with an intracellular 
pathogen directly by strategies leading to apoptosis of the infected cell. Their ability to attack 
any variety of cell possible is of crucial importance, as all types of cells are potential targets 
for an intracellular pathogen[28, 36, 37].  
 
1.2.4 B cells  
B cells are small cells that originate in the bone marrow. They function in the humoral 
immunity component of the adaptive immune system by secretion of antibodies[39]. 
 
The B-cell receptor (BCR) is a transmembrane receptor protein located on the outer surface of 
B cells. It consists of a membrane-bound immunoglobulin molecule and associated Igα and 
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Igβ heterodimers capable of signal transduction. The immunoglobulin contains a unique and 
randomly determined antigen-binding site that enables the receptor to specifically interact 
with just one type of antigen. The molecule is Y-shaped and consists of four polypeptide 
chains; two identical heavy chains and two identical light chains connected by disulfide 
bonds. Each heavy chain is made up of three constant domains and one variable domain, and 
each light chain is made up of one constant domain and one variable domain. One constant 
domain and one variable domain from each of the four chains make out the arms of the Y, 
which each contain one of two identical antigen-binding sites (fig. 1.4)[40].   
 
 
 
 
Figure 1.4. Schematic drawing of typical antibody molecule on the surface of a B cell: The 
antibody molecule is put together by four polypeptide chains. The two identical heavy chains  make 
out the stem and the hinge region. The N-terminal parts of a heavy and light chain together make out 
an antigen-binding site. The two antigen-binding sites are identical. Copyright 2008 by Pearson 
Education, inc., publishing as Benjamin Cummings.      
  
 
When the BCR interacts with membrane-bound antigen, a synapse is formed between the B 
cell and the surface of the pathogen. The transmembrane complex that is non-covalently 
associated with the membrane-bound antibody, containing intracellular immunoreceptor 
tyrosine-based activation motifs (ITAMs), will be activated by phosphorylation[39]. This 
creates a signaling cascade that leads to activation of genes associated with B cell activation. 
In addtion to these signals, most B-cells need additional signals from an antigen-specific 
helper T-cell to become activated[39].  
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After activation, and subsequent enconter with a matching antigen, the B-cell will multiply to 
create an army of identical cells that all recognize the same pathogen. This takes place  
through a process called clonal selection[39]. At the same time, the cells will differentiate into 
a state where the immunoglobulin part of the BCR is secreted in large amounts, instead of 
being attached to the cell surface[39]. The secreted immunoglobulins, or antibodies, will bind 
pathogens and either neutralize them, or prepare them for uptake and destruction by 
phagocytes[40].   
 
Neutralizing antibodies have the ability to prevent an infection, and mediates this by sticking 
to antigens on the surface of a pathogen and thereby immobilizing it. At present, the 
production of neutralizing antibodies against an infectious agent is the main aim of most 
vaccines. Antibodies can also, while bound to antigens with their antigen-binding region, bind 
to receptors on phagocytic cells with their Fc region, and thus serve as molecular adaptors. 
This will encourage white blood cells or macrophages to phagocytose, or eat, the pathogen. 
Having clumps of antibodies on the surface of a pathogen will serve as a signal to the body 
that intruders are present, and can thus recruit variant types of other immune cells as well. The 
result is either cytolysis, where proteins of the complement system lyse the cell, or cytotoxity 
mediated by varying effector cells[39, 40].  
 
 
1.3 APC-targeted DNA vaccines against influenza 
 
This section will focus on how the concept of DNA-based immunization can be used to create 
novel vaccines against influenza that are targeted to specific cell types in the body. An 
explanation of the DNA vaccination strategy will be presented, before its advantages and dis-
advantages concerning influenza prevention are discussed. Further, one of the strategies that 
can be applied for improved immunogenicity of DNA vaccines, is explained. Lastly, a 
vaccine strategy that enables the delivery of APC-targeted influenza vaccines will be 
introduced.    
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1.3.1 DNA vaccines  
DNA vaccination is the use of DNA plasmids to induce immune responses by direct injection 
into animals of DNA encoding antigenic proteins[41, 42]. The DNA will be introduced into 
appropriate tissues, and the cells present will start production of the antigen to which an 
immune response is sought[41, 42]. Immunization with this ”naked” DNA may be able to 
protect against human disease without many of the disadvantages associated with current 
vaccines, such as long production-time, low vaccine stability, and the use of infectious 
agents[43]. Although approved for use in some animals, no DNA vaccines are available for 
use in humans as yet. 
 
DNA vaccines can be rapidly constructed and manufactured, and could therefore offer a huge 
advantage should a pandemic influenza emerge[44]. Compared to generation of conventional 
influenza vaccines, DNA vaccines against influenza do not need to be grown in chicken eggs, 
which shortens the generation time drastically. A shorter production time will also solve the 
mismatch problem in annual influenza vaccines, between strrains to be included in the 
vaccines, and the actual circulating strains. The stability of DNA reduce the costs of 
manufacturing DNA vaccines as they can easily be stored and distributed[43]. This enables a 
large-scale manufacture of vaccines which again could potentially enable vaccination on a 
global scale. This would mean that a vaccine could be available for people in developing 
countries aswell, where they are needed the most. Use of plasmids offers a conceptually safer 
strategy for vaccination, as they are non-live and non-replicating, leaving little risk for 
secondary infection. Also, the genes can be produced without exposure to live pathogens and 
with high fidelity to the wild type proteins.  
 
A potential disadvantage with DNA vaccines is the concerns regarding whether the plasmid 
DNA can be integrated into genomes following vaccination[44]. This could potentially result 
in mutations and problems with replication of the host cell DNA, or result in chromosomal 
instability through the induction of chromosomal breaks or rearrangements. Another concern 
is that the inserted DNA might lead to insertional mutagenesis, by activation of oncogenes or 
the inactivation of tumor-supression genes[45]. Nonetheless, clinical trials with DNA 
vaccination applied in humans have investigated these concerns extensively and has so far 
found little evidence of integration[46, 47]. A second concern regards the potential of a DNA 
vaccine to induce anti-DNA immune responses, which would defeat the point of a vaccine as 
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a whole[44]. Research has as yet not reported immune responses against the introduced 
DNA[44, 48]. Based on this research, the main problem with DNA vaccines is not these slight 
risks, but instead their low immunogenicity[49, 50]. The low immunogenicity is hypothesized 
to stem, in part, from inefficient uptake of the plasmids by cells[45].  
 
1.3.2 APC-targeting  
Since the discovery of DNA vaccination, several advancements in antigen design, improved 
formulations, inclusion of molecular adjuvants, and physical methods of delivery have been 
made to improve immunogenicity[45]. One of the strategies that previously has shown to 
significantly increase immune responses after DNA vaccination, is targeting of the antigen to 
APCs[51]. Novel vaccine molecules have been generated that target antigen to APCs via a 
targeting unit directed against receptors expressed on their surface. The rational behind this, is 
to increase antigen uptake, and the subsequent presentation of peptides to CD4 and CD8 T 
cells. Cells transfected with plasmid DNA encoding the vaccine molecules will secrete the 
encoded vaccine proteins that are then targeted to different surface molecules on APCs 
(fig.1.5). After binding to surface molecules, the vaccine proteins are processed by the APCs, 
and peptides from the antigen unit is presented on either MHC class I or MHC class II 
molecules on the cell surface[52]. Targeting to different surface molecules will lead to 
different immune responses, depending on which type of MHC molecule that ends up 
presenting the antigen peptides[52].  
 
 
 
Figure 1.5: Secreted fusion proteins have the ability to target antigen-presenting cells by binding 
to surface molecules: The APC-targeted fusion proteins can be targeted to surface molecules on 
APCs and induce either B- or T cell responses. The fusion proteins are processed by the APC and 
peptides from the antigenic unit are presented on MHC I/MHC II molecules of the APC. Adapted 
from Grødeland et.al. (Grødeland 2015). 
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1.3.3 Vaccibodies 
 
A vaccibody is a targeted immunoglobulin-based homodimeric DNA vaccine that can be used 
to target antigens to various surface molecules on APCs[53]. The vaccibody homodimer 
(fig.1.6) are made out of three modules, each of them serving a purpose to increase efficacy. 
Two individual identical amino acid chains make out the homodimer[53]. Each of them has 
an N-terminal targeting unit, a dimerization unit composed of a shortened human Ig hinge and 
a CH3 domain from a human IgG, and an antigenic unit[51]. The targeting unit ensures the 
ability to attract and target APCs, which leads to an effective immune response. Binding to 
surface receptors will lead to a rapid internalization of the vaccibody and mediate maturation 
of the APC. Overall, this will enhance presentation of the antigenic unit to T cells[54]. The 
dimerization unit serves to connect the antigenic unit with the targeting unit, and also to 
fascilitate the dimerization of the two monomeric proteins into a homodimer, enabling 
bivalency[51]. Any intact protein antigen can be used in the antigenic unit, which, depending 
on the selected targeting unit, can stimulate both B- and T cell immunity[52].  
 
 
 
 
 
 
 
Figure 1.6. Overall structure of the vaccibody molecule: The vaccibody is a homodimer where each 
chain is composed of an amino-terminal targeting unit that binds surface molecules on APCs, a 
dimerization unit composed of a shortened human hinge and CH3 domain, and an antigenic unit 
composed of the relevant antigen. Adapted from Grødeland (Grødeland 2015).   
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1.4  Universal vaccines against influenza    
 
 
Current influenza vaccines primarily induce strain specific neutralizing antibodies[55]. Thus, 
vaccines against seasonal influenza have to be annually updated due to antigenic drift, and the 
vaccines are likely to offer no increased protection in the event of a novel influenza pandemic. 
Novel influenza vaccines that could offer broader protection are therefore important. The 
ultimate goal would be development of a vaccine that could be delivered once, and yet confer 
lifelong protection against influenza.  
 
A broad protection against influenza can be conferred by both broadly neutralizing antibodies 
and broadly protective T cells. The vaccine-induced antibodies will typically be specific for 
the globular head of HA. However, the globular head is highly prone to mutations, rendering 
the antibodies inefficient against next year’s influenza[56]. The stalk of HA is more 
conserved, but unfortunately also low immunogenic. In recent years, several studies have 
demonstrated such antibodies to be broadly protective[56, 57], but vaccine development using 
the stem as antigen has proven cumbersome[58, 59].  
 
T cells typically bind epitopes that are fairly conserved within a subtype of influenza, and can 
as such offer broader protection against influenza than antibodies[60]. However, T cells 
cannot block the viral entry of influenza virus, but they can greatly reduce disease burdens 
and confer protection against increased morbidity and mortality[61]. Thus, vaccines aiming at 
the induction of protective T cell responses could prove very useful for protection of the 
population against influenza. Below, several strategies for vaccines aiming at the induction of 
T cells will be introduced.  
 
1.4.1 Broadly protective vaccine antigens  
Most universal vaccine design approaches currently focus on generating cross-protective 
cellular immunity. One such strategy is to identify conserved sequences, which are similar 
sequences that occur across species, and use these as vaccine antigens ([57, 62]). T cell 
epitopes are commonly highly conserved on internal proteins between different strains of 
influenza viruses[60]. One example is the nucleoprotein (NP), which is a major target for 
immunodominant CD8 T cell responses during an influenza infection. NP has been shown to 
induce effective immune responses and protection against various influenza A subtypes[63].  
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Another strategy is to construct a consensus sequence, where the “average” of many 
hemagglutinin sequences are combined into one gene. One study with influenza involved 
using many H5N1 hemagglutinin sequences, in order to generate a codon-optimized gene that 
could generate a broad protection. The vaccine managed to elicit robust cross-protective 
immune responses in mice against divergent H5N1 influenza viruses[64].  
 
1.4.2 Mosaic vaccine antigens 
Recently, a novel mosaic antigen approach has been shown to induce T cell reactivity against 
a broader variety of epitopes as compared to other approaches[65]. In this method, a genetic 
algorithm is utilized in order to computationally design sequences that are similar to natural 
sequences, but that maximizes the coverage of potential T cell epitopes[66]. The strategy was 
first applied for development of novel HIV vaccines, which, as influenza, is a virus that 
diverges from year to year[65, 67, 68]. Co-circulating HIV strains differ from one another by 
20% or more in relatively conserved proteins and by up to 35% in their envelope protein, and 
the result is that each person infected with HIV have different versions of the virus[69].  
 
For designing an effective HIV vaccine that can make the immune system recognize the 
highly variable HIV antigens, mosaic sequences were generated that were optimized to 
include the maximum number of potential T-cell epitopes from a set of viral proteins and that 
showed better coverage than consensus sequences made from the same set of viral 
proteins[66]. The mosaic sequence has been put together using gene fragments from many 
different viruses, and encodes in sum a mosaic protein where conserved regions are favoured. 
The resulting recombinant protein will consist of peptides of a certain length (k-mers) that can 
all be found in the set of input sequences, as opposed to a consensus sequence, which is made 
out of the most frequent residu at each position[70]. The mosaics both resemble natural 
proteins and contain only natural fragments, and so intracellular processing and presentation 
on MHC molecules will resemble the processing of a natural pathogen[70], which might 
explain the broader protection compared to the consensus. Quite recently, the mosaic strategy 
was demonstrated to be effective also in the context of influenza[2].  
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1.5 Aims of the study  
 
As influenza viruses diverge by 1-2% each year[2], there is a need for novel influenza 
vaccines that can confer a broader protection against influenza. In this study, mosaic antigens 
were made using HA sequences from a collection of diverse influenza viruses. HA is the 
logical choice of antigen, as it is the most abundant surface molecule of influenza, and 
because it is responsible for the initial contact and fusion with influenza viruses. The mosaic 
HA genes will contain only natural T cell epitopes that were all present in the collection of 
HA sequences. The epitopes stimulating T cell responses will hopefully be the same epitopes 
that are processed and presented in natural influenza infections.  
 
The mosaic HA sequences were applied as antigenic units of vaccibodies. Recent experiments 
have shown that the choice of targeting unit can promote the formation of either dominant 
antibody responses or T cell responses[71]. The vaccibodies were therefore targeted to 
different surface molecules: the chemokine receptors CCR1, CCR3 or CCR5 by MIP1α, the 
chemokine receptor Xcr1, by XCL1, and to MHC class II molecules by a single chain 
variable fragment (scFv). Vaccibodes targeting the hapten NIP were constructed as a non-
targeted control.  
 
The aims of the study were to:  
 
1. Construct mosaic hemagglutinin antigens to be used as antigenic unit of Vaccibodies  
2. Construct Vaccibodies containing the modified hemagglutinin antigens  
3. Analyze the in vitro structural and functional properties of the novel vaccine proteins 
4. Investigate the vaccines’ ability to induce antigen-specific antibodies and T cell 
responses  
5. Examine influenza protection in mice following vaccination  
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2. Materials and methods 
 
This section will first describe the bioinformatic methods used for generation of the mosaic 
hemagglutinin antigens. Further, the laboratory techniques applied for construction of the 
novel vaccine proteins are listed. Lastly, the different techniques applied in animal 
experiments are presented. An introduction to each technique is briefly described prior to the 
following procedures. Where commercial kits were used, the supplied protocols from the 
manufacturer are referred to. 
 
2.1 Bioinformatic methods  
 
Before generation of the mosaic hemagglutinin genes, a total of 387 HA sequences were 
collected from the National Center for Biotechnology Information (NCBI) protein database. 
All available sequences that were complete and non-redundant were collected. The sequences 
collected represented all classes of HA except subgroup 18, for which there where no 
complete sequences. The optimized mosaic sequences were generated by a genetic algorithm 
using the Mosaic Vaccine Designer tool [72], and synthesized commercially (Genscript, 
USA).  
 
2.1.1 Building phylogenetic trees  
Phylogenetics is the study of evolutionary relatedness among organisms. Building of a 
phylogenetic tree can be used as a method to represent the genetic relationship between 
species. Before generation of phylogenetic trees for the HA subtypes, multiple alignments 
were performed using COBALT (Constraint-Based Multiple Alignment Tool[73]). The tool 
computes an alignment using conserved domain and local sequence similarity information. 
The alignment is then utilized for building of a tree that will visualize similarities between the 
sequences. This was performed using the Phylogenetic Tree operation in COBALT.    
 
Phylogenetic trees were build for subgroups of HA where numerous HA sequences were 
available for collection, in order get an overview of the genetic relations between the HA 
sequences in each subgroup. A selection of input sequences, sequences that was put into the 
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Vaccine Designer for generation of a mosaic, could then be chosen from the tree. Generation 
of phylogenetic trees were necessary for the subgroups H1, H2, H4, H5, H6, H7, and H9. For 
the remaning subgroups where few sequences were available, all collected sequences were 
used as input sequences.  
 
For generation of a mosaic based on only the HA1 subtype, (HA1), the selection of input 
sequences was made from the 167 sequences of the H1 subtype. In addition to the genetic 
similarity of the sequences, the year and location where the HA sequence was first detected, 
were also taken into account when selecting input sequences. A set of 18 H1 sequences were 
chosen for generation of HA1 with the Mosaic Vaccine Designer tool. The second mosaic, 
HA1-17, was constructed from a total of 112 HA sequences representing all 17 available HA 
subtypes. Phylogenetic trees were produced in the same way as for the H1 subgroup, and sets 
of input sequences from the H2, H4, H5, H6, H7, and H9 subgroups were chosen based on the 
same criteria. Together with these, all available sequences from the remaining H3, H8, H10, 
H11, H12, H13, H14, H15, H16, and H17 subgroups were also used as input sequences when 
generating the HA1-17 mosaic (table in Appendix 4).  
 
2.1.2 Mosaic Vaccine Designer 
The Mosaic Vaccine Designer tool uses the recently published ”mosaic” method to generate 
protein sequences that are optimized for high-frequency k-mers. It utilizes a genetic algorithm 
for optimizing of a vaccine antigen made from a population of artificial recombinants (fig. 
2.1). The recombined sequence population is generated using random two-point 
recombination of natural sequences in an input set. Four sequences are picked from the 
population (or one of them is picked from the natural input sequences), and the two ”better of 
pair” sequences are recombined in order to generate a ”child” sequence. Both the child and 
the parent sequences are scored by computing the coverage of k-mers. The coverage is 
defined as the mean fraction of natural-sequence k-mers included in the sequence, averaged 
over all natural sequences in the input data set. If the sequence coverage of the child exceeds 
that of any of the four randomly picked sequences, the lowest-scoring one is replaced with the 
child. This cycle of child generation is continued until improvement of k-mer coverage in the 
population ceases. The child with the highest score of epitope coverage will then be selected 
as the populations best representative and resulting sequence generated by the algorithm[70].  
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Figure 2.1. Schematic of how the mosaic vaccine designer generates mosaics: The mosaic vaccine 
designer generates mosaics from a set of natural input sequences that are recombined into recombined 
sequence populations. The recombined sequence populations evolve for improved epitope coverage by 
choosing two parent sequences that are recombined for generation of a child sequence. Figure adapted 
from Fischer (Fischer 2007).   
 
A number of parameters had to be set in the parameter options of the vaccine designer tool. 
Most importantly, the epitope length was set to 9 amino acids in an attempt to select for 
epitopes that are presented by both MHC class I and class II molecules, and thereby capture 
of both CD8 T cell epitopes and CD4 T cell epitopes. The cocktail size was set to 1 in order to 
generate a single peptide that represented all upploaded sequences. As the input set of 
sequences were relatively small, the rare threshold was set to the default value 1. When rare 
threshold is set to 1, every sequence with a length of 9 amino acids (9-mer) that exists in the 
input set will count in the score. These parameter settings will be further discussed in section 
4.1.1. The 18 H1 sequences were uploaded for generation of the HA1 mosaic, and the 112 
sequences collected from all available subgroups were uploaded for generation of the HA1-17 
mosaic. The resulting mosaic sequences are shown in Appendix 4: Results.  
 
2.1.3 Sequence alignments using BLAST  
Alignment of protein sequences was performed using Basic Local Alignment Tool 
(BLAST)[74]. BLAST is an algorithm for comparing sequence information and will find 
regions of local similarity between two sequences. The resulting alignment will display the 
differences in amino acid composition between sequences.  
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2.1.4 Coverage assessment using Epicover 
The Epitope Coverage Assessment Tool[75] fascilitates coverage comparisons for potential 
antigens. Coverage is defined as the mean fraction of natural-sequence 9-mers included in the 
antigen, averaged over all natural sequences in the input data set. The potential epitope cover 
by an antigen is calculated using the optimization metric used by the Mosaic Vaccine 
Designer tool. The tool calculates the fraction of 9-mers per sequence in the input set that are 
covered by the antigen. Both exact matches and near-matches contribute to the coverage of 
epitopes, due to the fact that similar epitopes may cross-react. In this study, both the off-by-1 
amino acid matches and the off-by-2 amino acid matches were included in the calculation of 
coverage.  
 
2.2 Cloning techniques  
 
Standard molecular biology techniques were used for construction of the novel vaccine 
proteins. The mosaic genes were delivered from Genscript in pUC57 vectors with flanking 
SfiI sites, and were subcloned into a pLNOH2 expression vector, using the corresponding SfiI 
restrictions sites.  
 
2.2.1 Restriction digest  
Restriction enzymes are naturally occurring enzymes able to cleave DNA molecules at their 
specific cleaving sites. In this study, a restriction digest was performed in order to cleave the 
HA sequences from the pLNOH2 and pUC57 vectors. The cleaving was performed with the 
restriction enzyme SfiI (BioNordika, NEB), which will cleave DNA at the sequence 
GGCCNNNN↓NGGCC, where N is any base and ↓ is the point of cleavage. The restriction 
digests were performed according to the following protocol.  
 
Protocol 
 
• In a 1,5 ml tube, combine the following:  
- 8 µl of plasmid DNA  
- 2 µl BSA 
- 2 µl NEB4  
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- 1 µl of SfiI  
- 7 µl of dH2O (= total volume of 20 µl) 
• Mix gently by pipetting.  
• Incubate tube at 50 °C for 1 hour, according to the manufacturer’s instructions. 
 
2.2.2 Agarose gel electrophoresis  
For separation of fragments from the digested DNA, a gel electrophoresis was performed.  In  
a gel electrophoresis, DNA fragments is separated according to size due to an electric current 
pulling them through a gel. The fragments will wander towards the positive cathode of the 
electrophoresis chamber due to the negatively charged phosphate backbone of DNA. The gel 
consists of a matrix of agarose, a polysaccharide polymer material extracted from seaweed. 
As the DNA moves through the matrix, the larger fragments are more likely to be impeded 
and slowed down by the gel, enabling separation of different sized molecules. In this 
experiment, a 2% agarose gel was cast according to the protocol in Appendix 2. A molecular 
weight standard was added to the gel in order to estimate the sizes of the different fragments. 
The fragment sizes was deduced by comparing bands from the respective samples with the 
bands of known sizes in the ladder. The bands corresponding to the appropriate fragment 
sizes could then be excised from the gel using a clean scalpel and stored.   
 
Gel extraction  
A gel extraction was performed in order to isolate the DNA fragments in the stored gel pieces. 
The isolation procedure was performed with a QIAquick Gel Extraction Kit (QIAGEN) and 
in accordance to the manufacturer’s protocol.  
 
2.2.3 Ligation  
For insertion of the mosaic HA antigens into the pLNOH2 vector, a ligation reaction was set 
up. The reaction was catalyzed by T4 DNA ligase (Roche), which is an enzyme isolated from 
bacteriphage T4. T4 DNA ligase is able to catalyze the formation of a phosphodiester bond 
between neighboring 3’-hydroxyl- and 5’-phosphate ends in doublestranded DNA. As a 
result, a covalent bond was formed between the DNA sequence encoding HA and the DNA 
sequence of the vector. The reaction was set up according to the following protocol.  
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Protocol  
 
• In a 1,5 ml tube, combine the following: 
- 1 µl of T4 DNA ligase (added last) 
- 2 µl of vector DNA (vaccibody) 
- 7 µl of insert DNA (mosaic) 
- 2 µl 10 x Ligation Buffer (Roche)  
- 8 µl nuclease-free water (= a total of 20 µl)  
• Mix all components by pipetting up and down and centrifuge briefly.  
• Incubate over night at 3-4 °C. 
 
2.2.4 Transformation  
The ligated plasmids were transformed into chemically competent cells called TOP10 cells 
(Invitrogen). These are chemically competent E.coli cells that are ideal for high-efficiency 
cloning and plasmid propagation. Transformation is the process by which foreign DNA is 
introduced into a cell. Transformation of TOP10 cells were used as the means of replicating 
the ligated pLNOH2 plasmids, in order to increase the amount of DNA. This was possible 
because the pLNOH2 vector contains a bacterial origin of replication, in addition to the 
mammalian origin. It also carries an ampicillin resistance gene, enabling positive selection of 
the bacteria that has been successfully transformed. Only cells containing the plasmid were 
able to grow and form colonies when plated onto agar plates containing ampicillin.  
 
Protocol  
 
• Take the competent TOP10 cells out of -80 °C and thaw on ice (approximately 10-15 
min).  
• Mix 1-2 µl of ligation reaction into one tube of competent TOP10 cells.  
• Place the cells/DNA mixture on ice for 20-30 minutes.  
• Heat-shock the transformation tubes by placing them in a 42 °C heating block for 
exactly 45 seconds.  
• Put the tubes back on ice for a few minutes. 
• Add 500 µl of 1xLB media and grow in a 37 °C heat block for 45 minutes.  
• Centrifuge the tubes at 3000 rpm for 3 minutes to pellet the bacteria. 
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• Discard media until ~ 100 µl is left and resuspend the bacterial pellet. 
• Plate the transformation onto agar plates containing ampicillin.  
• Incubate plates over night at 37°C.  
 
Isolation of DNA  
The plasmids were isolated from the bacterial cells using a small-scale isolation technique 
(miniprep). The Wizard Plus SV Miniprep kit (Promega) applied, are able to yield a 
concentration of 50-100 µg of DNA. The procedure was performed according to the 
manufacturer’s protocol.  
 
2.2.5 Diagnostic restriction digest  
A diagnostic restriction digest was performed by cutting the plasmid into specifically sized 
pieces prior to analysis of the resulting fragments using gel electrophoresis. The procedure 
was performed in order to verify the presence of the inserted fragment, encoding the mosaic 
HA, in the pLNOH vector. The plasmid was cut using enzymes with restriction sites both 
inside and outside of the inserted fragment. By running the cut plasmids on a gel, the sizes of 
the fragments, and thereby the presence of the insert, can be deduced. The restriction enzyme 
BsmI (BioNordika, NEB),  has a cut site 585 bp into the HA1 mosaic and was used to cut the 
plasmids containing it. The enzyme will cleave at the DNA sequence G↓GATCC, where N is 
any base and ↓ is the point of cleavage. The plasmids containing HA1-17 were cut with BamHI 
(BioNordika, NEB), which cuts at 515 bp into the inserted mosaic fragment, at the DNA 
sequence GAATG↓C. The restriction was performed according to the protocol in section 
2.2.1.  
 
2.2.6 DNA sequencing   
DNA sequencing was performed in order to determine the precise order of nucleotides in the 
vaccine plasmids. This was done as an additional test to verify that the vaccibody constructs 
contain the correct HA antigen and targeting unit. The method used for sequencing is the 
Sanger method, which involves in vitro synthesis of the DNA to be sequenced. The 
sequencing was performed by GATC Biotech (GATC, Germany). Purified plasmids were 
premixed with primer and shipped in 1,5 ml tubes. The three different sequencing primers 
applied were diluted to 5 uM before use. The 5’ pLNO primer initiates synthesis of the 
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targeting unit from the 5’. The 3`C pLNOH2 will start sequencing from the 3’ end of the 
inserted fragment. A third primer, GATC-5’hlhinge-115298, will initiate sequencing from the 
5’ of the hinge region. The DNA sequences of the primers are listed in table 1.  
 
Table 1. Primers used in the sequencing of ligated vaccine plasmids and their DNA sequences  
 
After receiving the sequencing results, in vitro sequences were aligned with the known 
sequences of the mosaic genes and targeting units. A high match between the sequences 
verify that the cloning of vaccine constructs has been successful.  
 
2.3 Sandwich ELISA  
 
The enzyme-linked immunosorbent assay (ELISA) is a test that utilizes antibodies and color 
change to identify a substance. Performing an ELISA involves at least one antibody with 
specificity for a particular antigen and usually a polystyrene microtiter plate used as a solid 
support. In a sandwich ELISA, a capture antibody is attached to the microtiter plate before 
addition of the antigen. A blocking buffer is added to prevent unspecific binding of antibodies 
to the wells. The proteins in the blocking solution will bind the area of the well not occupied 
by the capture antibody. The samples containing the antigen can then be added to the wells. 
Addition of a specific biotinylated detection antibody will trap, or ”sandwich”, the antigen in 
between the two antibodies (fig. 2.2). For detection, an enzyme-linked secondary antibody 
that binds non-specifically to the primary antibody is added. Addition of the enzyme substrate 
will create a color signal that gives quantitative information about the antigen.  
 
Primer	   Sequence	  
5’ pLNO  TCA CAG TAG CAG GCT TG 
3`C pLNOH2 ATG GCT GGC AAC TAG AAG 
GATC-5`hlhinge-115298 GAGAGGGTCTTCTGGCTT 
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Figure 2.2. Overview of the Sandwich ELISA format: The antigen is bound between two primary 
antibodies; a capture antibody and a biotinylated detection antibody. The antigen is detected indirectly 
by an enzyme-linked secondary antibody. Addition of the enzyme substrate creates a color signal. 
Copyright 2015 by Mabtech [76] 
 
Protocol  
 
• Add 100 µL of capture antibody (diluted in PBS azid) to each well, cover the plate, 
and incubate ON at 4°C.  
•  Add 200 µL of blocking buffer (recipe in Appendix 3) to each well, cover the plate, 
and incubate at RT for 1 hour.  
• Thoroughly decant solution from wells and wash 3 times with ELISA wash buffer 
(recipe in Appendix 3). 
• Add samples (SN or serum) and perform appropriate dilutions in ELISA buffer (recipe 
in appendix 3).    
• Cover plate and incubate for 2 hours at RT.  
• Thoroughly decant solution from wells and wash as before. 
• Add 100 µL detection antibody to each well, cover the plate, and incubate for 1 – 1½ 
hour at RT. 
• Thoroughly decant solution from wells and wash as before.  
• Add 100 µL of diluted strep-ALP (GE Healthcare) (1:3000 in ELISA-buffer) to each 
well, cover the plate, and incubate for 40 minutes at RT. 
• Prepare 1 mg/ml of phosphatase substrate in substrate buffer (recipe in appendix 3).  
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• Add 100 µL of substrate solution (1 mg/ ml) to each well and develop until wells turn 
yellow.  
• Read the absorbance at 405 nm with an ELISA plate reader at appropriate time points.   
 
2.3.1 ELISA for detection of vaccine proteins  
Three different ELISA assays were in this study applied for examinations of proper structure 
and function of the vaccine proteins. Supernatant was collected from transiently transfected 
HEK293E cells. The cells were grown in complete tissue culture medium: RPMI-1640 
containing 10% FCS and supplements (ThermoFischer). 1 µg of DNA was used per well of a 
24 well flat bottom cell culture plate (Corning Costar cell culture plate, Sigma-Aldrich). Each 
well was seeded with 2x105 cells and transfected the next day. Supernatants for use in 
sandwich ELISA were collected after 3 and 7 days. All ELISA assays were performed 
following the above protocol.  
 
Test of secretion of vaccine constructs in vitro  
In this assay, microtiter plates were coated with MCA878 (1:1000) (Bio-Rad), an anti-human 
IgG specific for the dimerization unit of the vaccibodies, and detection was performed using a 
mAb specific for the Fc-region of human IgG (1:1000) (HP6017-bio, Sigma-Aldrich). Both 
antibodies bind the dimerization unit of the vaccibodies. Supernatant containing αMHCII-
HAPR8 was used as a positive control, and supernatant with no DNA added was used as a 
negative control (mock).  
 
Test for presence of correct targeting unit in MIP1α- and αNIP-targeted vaccines  
In a second ELISA assay, two microtiter plates were coated with either hCCL3/MIP1α 
antibody (1:1000) (R&D Systems),  or NIP-BSA, in order to verify the presence of the αNIP - 
and MIP1α targeting units. All eight constructs and a mock were added to both plates along 
with positive controls containing the targeting unit used as coat (either αNIPpos or MIP1αpos). 
Detection was performed with HP6017-bio (1:1000).  
 
Test of the vaccine constructs’ binding capacitites  
Two microtiter plates were coated with the capture antibody MCA878 (1:1000) and 
supernatant containing each of the eight constructs. Supernatant containing αMHCII-HAPR8 
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was used as a positive control in the first plate, and a biotinylated mAb specific for HA of 
PR8 (1:1000), (H36-4-52-bio), was used as detection antibody. Supernatant containing αNIP-
HACal07 was used as a positive control in the second plate, and detection was performed with a 
biotinylated mAb specific for HA of Cal07 (1:1000).  
 
2.3.2 ELISA for detection of serum antibodies  
Sandwich ELISA using serum samples collected from vaccinated BALB/c mice was 
performed in order to measure serum antibodies against different virus HA. ELISA plates 
were coated with either inactivated PR8 virus (1:1600) (Charles River Laboratories), 
recombinant HA from Cal07 (0,5 µg/ml) (A/california/07/2009, Sino Biological Inc), or 
recombinant HA from H5N1 (0,5 µg/ml) (A/Vietnam/1194/2004, Sino Biological Inc). The 
protocol above was followed, except detection was performed using an antibody produced in 
goat, anti-mouse IgG (Fc-specific)-Alkaline phosphatase antibody (Sigma-Aldrich), that are 
specific for the Fc-region of mouse IgG and conjugated with alkaline phosphatase (1:5000).  
 
2.4 ELISpot assay  
 
For monitoring cell-mediated immunity, an Enzyme-Linked Immunospot assay can be 
applied due to its sensitive and accurate detection of rare antigen-specific T cells. The 
ELISpot assay (fig. 2.3) employs a technique very similar to the enzyme-linked 
immunosorbent assay (ELISA). A capture antibody with specificity for a certain analyte is 
coated onto a PVDF-backed microtiter plate. The plate is then blocked with serum protein 
that is non-reactive with any of the antibodies in the assay. Cells of interest are plated out at 
varying densities in the presence of varying stimuli. The proteins secreted by the cells will be 
captured by specific antibodies on the surface. Detection is then performed in a procedure 
similar to that employed by ELISA, leading to an end result where visible spots on the surface 
corresponds to a cytokine-producing T cell. The spots correspond to the frequency of 
cytokine-secreting cells at the single-cell level.   
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Figure 2.3. Schematic illustration of the principle of the ELISpot assay: Cells are cultured on a 
surface coated with a capture antibody specific for a certain analyte. Proteins, such as cytokines, are 
secreted by the cells and captured onto the surface. The secreted molecules (analyte) are detected 
using a biotinylated detection antibody, and followed by a streptavidin-enzyme conjugate. A 
precipitating substrate is added in order to create visible spots on the surface. Copyright 2015 by 
Mabtech[77]  
 
In this study, plates precoated with anti-mouse IFN-γ, Mouse IFN-gamma ELISpot PLUS kit 
(ALP) (Mabtech), was applied. Blocking was performed with complete tissue culture medium 
(RPMI-1640 containing 10% FCS and supplements). Spleenocytes harvested from HA1-
vaccinated mice at day 28 following vaccination were added to the plates (protocol in 
Appendix 2). The cells were stimulated to produce IFN-γ by recHA of H1N1 A/Puerto 
Rico/8/34 (Sino Biological Inc), recHA of H1N1 A/California/7/2009 (Sino Biological Inc), 
recHA of H5N1 A/Vietnam/1194/2004 (Sino Biological Inc), and recHA of H7N9 
A/Shanhai/1/2013 (Sino Biological Inc). All protein concentrations were 10 µg/ml. As a 
positive control, cells were stimulated with ConA, which gives an unspecific activation of the 
cells. Cells without stimulation were used as negative control, in order to indicate the number 
of spontaneously secreting cells. Detection was performed with biotinylated anti-mouse IFN-γ 
and with streptavidin-horse radish peroxidase (strep-HRP) (GE Healthcare). The ELISpot 
was performed in accordance to the manufacturers protocol, and spots were counted in an 
Immunospot ELISpot reader (CTL).  
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2.5 Animal experiments 
 
6-8 weeks old female BALB/c mice (Taconic, Denmark) were used in all animal experiments. 
Mice were kept at the Department of Comparative Medicine, Oslo University Hospital. 
Vaccination experiments were performed in the minimal disease unit (MDU), where the mice 
were regularly tested for pathogens to meet the Federation of European Laboratory Animal 
Science Association (FELASA) guidelines for health monitoring. Prior to challenge, the mice 
were transferred to the infectious unit (INF) at the Centre of Comparative Medicine. All 
animal experiments were approved by the National Committe for Animal Experiments (Oslo, 
Norway).  
 
2.5.1 Intradermal vaccination  
Intradermal injection is the injection of a substance directly into the dermis of the skin, just 
below the epidermis. For intradermal delivery of vaccine, 6 BALB/c mice per group were 
anaesthetized by intraperitoneal (i.p.) injection of 150 µl of ZRF and shaved in the lower back 
region. DNA plasmids dissolved in NaCl were injected intradermally on each flank of the 
mouse (a total of 25 µg DNA per mouse). Skin electroporation (EP) with DermaVax 
(Cellectis) was performed immediately after injection, in order to increase uptake of DNA by 
skin cells.  
 
2.5.2 Intramuscular vaccination  
Intramuscular injection is the injection of a substance directly into a muscle. For 
intramuscular delivery of vaccine, 6 BALB/c mice per group were anaesthetized by i.p. 
injection of 150 µl of ZRF and shaved on the outer side of each hind leg. 25 µl of plasmids 
dissolved in NaCl were injected intramuscularly on each leg (a total of 50 µg of DNA per 
mouse). Skin electroporation (EP) with an ELGEN pulse generator (INOVIO 
Pharmaceuticals) was performed immediately after injection with needles long enough to 
penetrate the muscle.  
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2.5.3 Blood sampling  
Blood samples were collected by puncture of the sapheous vein. The mouse was restrained in 
a plastic tube with an air hole in the end. The leg was shaved in the direction of hair growth 
with a scalpel blade until vein was visible. The scalpel was held as flat as possible in order to 
prevent cuts. The vein was then punctured with a needle held approximately 90 degrees to the 
skin and the blood was collected in numbered microcentrifuge tubes.  
 
Separating serum from blood cells 
After collection of blood samples, the tubes were centrifuged in a table top centrifuge at 13 
000 rpm for 10 minutes. The resulting supernatant was collected and transferred into a clean 
microcentrifuge tube. Centrifugation was repeated and supernatant (serum) was collected into 
a third tube. The serum was stored at -20°C.   
 
2.5.4 Viral challenge  
Groups of vaccinated mice (n = 6/group) were anaesthesized by i.p. injection of 150 µl of 
ZRF prior to challenge with influenza. The mice were infected intranasally with 5xLD50 of 
either A/Puerto Rico/8/1934 or A/H1N1/Cal/07/09 in 10 µl per nostril at 4 weeks past 
vaccination. Mice were monitored for weight loss with an end point of 20% weight reduction, 
as required by the National Committe for Animal Experiments. Mice reaching the limit of 
>20% weight loss were euthanized by either cervical dislocation or by use of a CO2 chamber.  
 
2.6 Statistical analyses  
 
The data produced by the ELISpot was analyzed using a Mann-Whitney test. Standard 
deviation (SD), standard error of the mean (SEM), were calculated by GraphPad Prism 6.   	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3 Results  
 
 
The main objectives of this thesis are: (1) to construct the mosaic hemagglutinin antigens and 
the modified influenza vaccine constructs, (2) to demonstrate correct folding and receptor 
binding for the vaccine constructs, (3) show that mice immunized with the novel vaccines can 
induce relevant antibodies and T cell responses. 
 
3.1 Construction of mosaic hemagglutinin antigens  
 
3.1.1  Phylogenetic trees of collected hemagglutinin sequences  
Two mosaic antigens were generated using the Mosaic Vaccine Designer tool. One was based 
on hemagglutinin sequences from the H1 subtype (HA1). The second one was based on 
hemagglutinin sequences from 17 subtypes of HA (HA1-17). A phylogenetic tree was made for 
all collected H1 sequences, and the more distantly related sequences were manually selected 
as input sequences for insertion into the Mosaic Vaccine Designer tool. For generation of the 
HA1-17 mosaic, phylogenetic trees were made for subtypes H2, H4, H5, H6, H7, and H9. 
Sequences were collected manually from each tree and used as input sequences. Figure 3.1 
shows the tree built for the H5 subtype, and the other trees are shown in Appendix 4: Results.  
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Figure	   3.1.	   Phylogenetic	   tree	   of	   collected	   H5	   sequences:	   Phylogenetic	   tree	   displaying	   the	  evolutionary	  relationships	  between	  77	  H5	  sequences	  collected	  from	  the	  NCBI	  protein	  database.	  Underlined	  sequences	  were	  selected	  to	  be	  used	  as	  input	  sequences.	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3.1.2 Alignments  
The two mosaic antigens made with the Mosaic Vaccine Designer contains only natural T cell 
epitopes, but are still novel sequences. Pairwise sequence alignments were performed for both 
antigens against the hemagglutinin protein sequences of A/Puerto Rico/8/1934 (PR8) and 
A/California/07/09 (Cal07), in order to identify regions of similarity between the viral 
sequences and each mosaic. These viruses were later applied in viral challenge with mice 
vaccinated with the mosaic antigens. Regions of similarity indicate evolutionary relationships 
between the sequences, and also functional and structural similarities. The alignments show 
that differences between the aligned sequences is found predominantly in the variable region 
of hemagglutinin, that encodes the globular head region. Less differences are found in the 
conservative region, that encodes the stalk domain of HA (fig. 3.2). 
  
 
  
 
 
 
 
 
A
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Figure 3.2. Alignment of hemagglutinin sequences: Alignments of the protein sequences of A) HA1 
against H1 (PR8) and H1 (Cal07), and B) HA1-17 against H1 (PR8) and H1 (Cal07). Differing amino 
acids are shown in red, and the amino acids encoding the globular head domain are shown with a grey 
background.  
 
 
3.1.3 Epitope coverage assessment  
The Epicover tool was used in order to compute the coverage of epitopes in a population by 
the mosaic genes. Coverage is defined as the mean fraction of natural-sequence 9-mers 
included in the antigen, averaged over all natural sequences in the input data set. As similar 
epitopes may cross-react, near-matches that were off-by-1 and off-by-2 amino acids were 
included. The coverage of the HA1 input set epitopes was calculated for HA1 and HA of PR8 
(fig. 3.3). Followingly, the coverage of the epitopes in the HA1-17 input set was calculated for 
HA1-17 and HA of PR8 (Appendix 4). For both input sets, the mosaic hemagglutinin antigen 
gave a higher coverage than HA of PR8. 
 
 
B
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Figure 3.3. Epitope coverage of HA1 and H1 (PR8): Calculation of coverage for two influenza 
antigens: A) The mean fraction of natural-sequence 9-mers shared with HA1 averaged over all 
sequences in the HA1 input set, and B) The fraction of 9-mers shared with H1 (PR8) averaged over all 
sequences in the HA1 input set. Both exact matches (red), off-by-one matches (orange) and off-by-2 
matches (yellow) were included in the score.  
 
 
3.2 Characterization of vaccine constructs  
 
We have subcloned the HA1 and HA1-17 mosaics on SfiI-sites into pLNOH2 vectors containing 
a previously described vaccine format that was designed to target antigens to various 
receptors on APCs[51, 53]. The mosaic was here equipped with four different targeting units;  
MIP1α[54], XCL1[78], αMHCII[51] and αNIP[51]. MIP1α and XCL1 are chemokines that 
target the chemokine receptors CCR1/3/5 and Xcr1, respectively. An MHC class II specific 
scFv was used for targeting to MHC class II molecules, and a scFv against the hapten NIP 
was utilized as a non-targeted control. The eight resulting vaccine constructs are listed in table 
1.  
 
 
 
 
 
 
 
Supernatants of 293E cells transiently transfected with the eight different vaccine plasmids, 
were tested using different sandwich ELISA assays. The ELISAs were performed according 
to the protocol in the methods chapter (section 2.3).    
A B
 Mosaic HA1 Mosaic HA1-17 
αNIP αNIP-HA1 αNIP-HA1-17 
MIP-1α  MIP-1α-HA1 MIP-1α-HA1-17 
XCL1 XCL1-HA1 XCL1-HA1-17 
αMHCII αMHCII-HA1 αMHCII-HA1-17 
Table 1: List of the mosaic vaccine constructs.  	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An ELISA assay was performed with coating and detecting antibodies against the 
dimerization unit, in order to assess the secretion efficacy of the constructed vaccines. The 
measured OD levels were plotted against the dilution factor (fig.3.4A). The result 
demonstrated efficient secretion of all eight constructs in vitro, although differing OD values 
indicated that some vaccine proteins were secreted more readily than others. The αMHCII-
HA1, XCL1-HA1-17, and MIP1α-HA1-17 were all expressed better than the positive control 
plasmid, and the NIP-targeted constructs were expressed more poorly than the others. The 
positive control (αMHCII-HAPR8), previously shown to be secreted by 293E cells[79], 
confirmed that the ELISA was working properly, and the low value for mock indicates that 
there were no false-positive results and little non-specific binding. Other ELISA assays were 
performed in order to verify insertion of the αNIP - and MIP1α targeting units into the 
vaccine proteins. The high OD values measured for the αNIP-HA1, αNIP-HA1-17 (fig. 3.4B), 
MIP1α-HA1, and MIP1α-HA1-17(fig. 3.4C) constructs, compared to the other samples, verified 
the presence of the correct targeting unit. A high OD value for the positive controls (MIPPos 
and NIPPos) confirmed that the ELISA was working properly for both plates, and low OD 
values for mock indicated that the targeting units were not falsely detected. We concluded 
from these results that all vaccine constructs were able to be secreted in vitro, and that the 
MIP1α- and αNIP-targeted vaccines contained the correct targeting units. As the NIP-
targeted constructs were able to bind NIP, we assume a correct folding of the αNIP-
constructs.   
  
In order to examine whether antibodies against HA of the H1 subtype could bind the mosaic 
antigens, ELISAs were set up with mAb against the dimerization unit as coat, and with mAb 
against HA from PR8 and Cal07 for detection. The modified vaccine constructs could not be 
recognized by the mAbs specific for H1 HAs (fig. 3.5). The high OD levels detected for the 
positive controls indicate that the ELISA had been functional. The lack of response from the 
negative control (mock) indicated that there was little non-specific binding. We concluded 
from this result that the modified hemagglutinin antigens have different binding capacities 
than the HAs of PR8 and Cal07.  
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Figure 3.4. Detection of vaccine proteins secreted in vitro: ELISAs performed on dilutions of 
supernatants from transiently transfected 293E cells. A) ELISA plates were coated with the capture 
antibody MCA878 and detection was performed using HP6017-bio, both antibodies binding the 
dimerization unit of the vaccibodies. B) ELISA plate was coated with αNIP and detected with 
HP6017-bio. C) ELISA plate was coated with MIP1α and detected with HP6017-bio.  
 
A
B
C
	   53	  
 
Figure 3.5. Secreted vaccine constructs were not detected with antibodies specific for H1 HA: 
Sandwich ELISAs performed on dilutions of supernatant from transient transfection of 293E cells. 
Plates were coated with MCA878, and detected with mAb against A) PR8, and B) Cal07.   
 
3.3 Vaccination with mosaic vaccine constructs induces humoral 
responses in mice   
 
While the mosaic HA could not be bound by mAbs against H1 HAs, it is conceivable that the 
mosaic antigens could nevertheless induce antibodies specific for various HAs in vivo. Thus, 
ELISAs using serum samples from mice vaccinated with the novel vaccine constructs were 
performed in order to measure serum antibodies against HA of a variety of viruses. A positive 
control group was vaccinated with the MCHII-HAPR8 plasmid, and a negative control group 
was vaccinated with NaCl. αMCHII-HAPR8 was used as positive control since it has 
previously shown to induce complete protection against a lethal dose of PR8[71, 79].  
 
3.3.1 Vaccination with HA1 enhances antibody titers following intradermal 
and intramuscular delivery  
 
ELISAs were performed with sera from mice vaccinated with the HA1 mosaic in order to 
measure the ability of the HA1 vaccines to induce antibodies. 36 BALB/c mice (n = 6/group) 
were injected once intradermally with either MIP1α-HA1, XCL1-HA1, αMHCII-HA1, αNIP-
HA1, or αMHCII-HAPR8 plasmids, along with NaCl as a negative control. Another 36 BALB/c 
A B
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mice (n = 6/group) were injected once intramuscularly with the same plasmids and NaCl. The 
vaccinations were performed as decribed in the methods chapter (section 2.5.1 and 2.5.2).  
 
In order to investigate induction of PR8-specific antibodies, antibody titers were measured for 
sera collected 1, 2, and 4 weeks following a single vaccination(fig. 3.6). This ELISA assay 
showed that there was a slight increase in sera of PR8-specific antibodies during these four 
weeks for mice vaccinated with MIP1α-HA1, XCL1-HA1, and αNIP-HA1, both intradermally 
and intramuscularly. The αMCHII-HAPR8 largely enhanced large antitbody titers against PR8 
for both delivery strategies. The intramuscular vaccination gave higher titers than the 
intradermal vaccination with αMCHII-HAPR8, and slightly higher titers with MIP1α-HA1, 
XCL1-HA1, and αNIP-HA1. αMCHII-HA1 failed to induce antibodies against PR8 in both 
experiments.  
 
 
Figure 3.6. Increase in PR8-specific titers following intradermal and intramuscular vaccination 
with HA1: Microtiter plates were coated with PR8 and detection was performed with anti-mouse IgG 
A
B
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in order to investigate induction of PR8-specific antibodies following i.d. and i.m. delivery of HA1. 
Titers were measured for all constructs at week 1, 2, and 4 for intradermally (A) and intramuscularly 
(B) vaccinated mice. Titers were given as the last serum dilution giving an absorbance above 
background (mean absorbance for NaCl-vaccinated mice plus five-times SEM). The right figures 
show only the mosaic vaccine constructs and NaCl. 
 
 
In order to examine antibody responses against HAs of relevant influenza strains, ELISA 
plates were coated with either inactivated PR8 virus, recombinant HA of Cal07 or 
recombinant HA of H5N1. Serum samples from week 4 after vaccination were analyzed for 
HA-specific IgG. The positive control plasmid, αMHCII-HAPR8, induced high titers against 
PR8, and thus confirmed functional vaccination. Similar to the responses measured above 
(fig. 3.6), the other vaccine constructs could only induce minute responses against PR8. 
Nevertheless, there seemed to be an increased effect after targeting of mosaic HA to 
chemokine receptors after i.m. vaccination.  
 
When examining antibody responses against Cal07, the positive control, αMHCII-HAPR8, 
failed to induce significant antibody titers. Interestingly, targeting of mosaic HA to 
chemokine receptors increased antibody responses, with XCL1-HA1 being particularly 
noteworthy after i.d. vaccination, and MIP1α-HA1 after i.m. vaccination. The increased effect 
of MIP1α-HA1 also held true for measurements of antibodies against HA from H5 influenza. 
The intramuscular vaccination gave overall higher titers against H1 (Cal07) and H5 (H5N1), 
than the intradermal vaccination (fig. 3.7B). In sum, targeting of mosaic HA with MIP1α 
seems particularly efficient, but XCL1-HA1 and αNIP-HA1 can also raise cross-reative 
antibodies.  
 
For further assessment of antibody responses after i.m. vaccination, ELISAs against recHA 
(Cal07) and recHA (H5N1) was performed in sera collected on days 7, 14 and 27 after 
vaccination. Interestingly, MIP1α-HA1 demonstrated increased responses against both HA 
from H5 and Cal07, as compared to all other vaccines. However, a closer examination 
showed that at day 14, XCL1-HA1 induced the highest antibody titers (fig. 3.8A and B). The 
results will be further discussed in the last chapter (section 4.2.3). 
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Figure 3.7. Induction of cross-protective antibodies following intradermal and intramuscular 
delivery of HA1: Microtiter plates were coated with PR8, recHA (Cal07), and recHA (H5N1) and sera 
collected 4 weeks past vaccination were added from mice vaccinated i.d. with HA1 (A), or from mice 
vaccinated i.m. with HA1 (B). Detection was performed with anti-mouse IgG. Titers are given as the 
last serum dilution giving an absorbance above background (mean absorbance for NaCl-vaccinated 
mice plus five-times SEM). 
 
 
 
Figure 3.8. Intramuscular delivery of HA1 induce titers against Cal07 and H5N1:  
coat: H1 (PR8) coat: H1 (Cal07) coat: H5 (H5N1)
A
B
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Microtiter plates were coated with recHA (Cal07) (A) or recHA (H5N1) (B) and sera collected from 
mice vaccinated i.m. with HA1 at week 1, 2, and 4 were added. Detection was performed with anti-
mouse IgG. Titers are given as the last serum dilution giving an absorbance above background (mean 
absorbance for NaCl-vaccinated mice plus five-times SEM). 
 
 
3.3.2 Vaccination with HA1-17 enhances antibody titers following 
intradermal delivery 
 
ELISAs were performed with sera from mice vaccinated with the HA1-17 mosaic in order to 
measure the ability of the HA1-17 vaccines to induce antibodies. 36 BALB/c mice (n = 
6/group) were injected once intradermally with the MIP1α-HA1-17, XCL1-HA1-17, αMHCII-
HA1-17, αNIP-HA1-17, and αMHCII-HAPR8 plasmids, along with NaCl as a negative control, as 
described in the methods chapter (section 2.5.1). After the initial immunization, a booster 
injection was given at day 30 for re-exposure to the immunizing HA antigen, in an attempt to 
increase antibody responses.  
 
ELISA plates were coated with either inactivated PR8 virus, recombinant HA of Cal07 or 
recombinant HA of H5N1, in order to investigate induction of cross-reactive antibodies 
during the 8 weeks following vaccination. The first immunization induced only low titers 
against all three HAs, but the second immunization boosted antibody responses (fig. 3.9.). 
However, it does not appear to be significant differenes between the groups. Of note, 
vaccination with αMHCII-HA1-17 did in this experiment induce antibody titers comparable to 
that of the other APC-targeted groups. This is in contrast to the complete lack of induced 
immune responses that were observed above with αMHCII-HA1.  
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Figure 3.9: Increase in antibody titers following intradermal vaccination with HA1-17: Mice 
immunized i.d. with HA1-17 were assayed for total IgG against A) inactivated PR8, B) recHA (Cal07), 
and B) recHA (H5N1) in order to investigate induction of antibodies. Titers were measured for all 
constructs at week 1, 2, 4, 5, 7, and 8 and given as the last serum dilution giving an absorbance above 
background (mean absorbance for NaCl-vaccinated mice plus five-times SEM). 
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The HA1-17 vaccines were able to induce only low titers against PR8, but higher titers against 
H5 (H5N1) and H1 (Cal07). For a closer examination of the observed responses, we re-
examined the measurements from weeks 4 and 8 after vaccination (fig. 3.10). The effect of 
APC-targeting is somewhat varied. In the ELISA with a coat of PR8, αNIP-HA1-17, XCL1-
HA1-17 and MIP1α-HA1-17 all induces similar antibody levels at week 4 post-vaccination. 
However, after the boost at week 8, the responses of XCL1-HA1-17 and MIP1α-HA1-17 are 
markedly increased above that of the non-targeted control. In the ELISA with a coat of Cal07, 
there is a large difference between the APC-targeted vaccines and the non-targeted control 
(αNIP-HA1-17). At week 4, the responses after XCL1-HA1-17 has not yet emerged, but these are 
well developed after the second vaccination in week 8. Interestingly, in this assay, it appears 
that αMHCII-HA1-17 induces the highest levels of antibodies, but MIP1α-HA1-17 and XCL1-
HA1-17 are also markedly present. A targeting effect may also be observed for the H5 (H5N1) 
assay, as the non-targeted control group induced lower antibodies than all targeted vaccine 
proteins, except for XCL1-HA1-17, which gave similar titers.  
 
 
Figure 3.10. Induction of cross-protective antibodies following intradermal delivery of HA1-17: 
Microtiter plates were coated with inactivated PR8, recHA (Cal07), or recHA (H5N1) and added sera 
from mice vaccinated i.d. with HA1-17 in order to detect induction of cross-protective antibodies. Titers 
were measured at week, 4 when the mice had only received the 1. vaccination dose (A), and at week 8 
(4 weeks after the 2. vaccination dose) (B). Detection was performed with anti-mouse IgG. Titers are 
coat: H1 (PR8) coat: H1 (Cal07) coat: H5 (H5N1)
A
B
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given as the last serum dilution giving an absorbance above background (mean absorbance for NaCl-
vaccinated mice plus five-times SEM). 
 
 
 
3.4 Targeted delivery of HA1 with MIP1α  and XCL1 increase T 
cell responses   
From the above ELISAs, MIP1α-HA1-17 and XCL1-HA1-17 appear to be the more promising 
vaccines that encodes mosaic HA. Thus, an ELISpot assay was performed in order to quantify 
the ability of MIP1α-HA1, XCL1-HA1, and αNIP-HA1 to activate IFNγ-secreting cells (fig. 
3.11). 24 mice (n=6/group) were injected once with 25µg DNA/EP as indicated in the 
methods chapter (section 2.5.1), and the ELISpot was performed according to the protocol in 
the methods chapter (section 2.4). Mouse spleens were harvested 4 weeks after i.d. 
vaccination with MIP-1α-HA1, XCL1-HA1, αNIP-HA1, and NaCl (protocol in Appendix 2).  
Cells were stimulated in vitro with recombinant HA proteins from PR8, Cal07, H5N1, and 
H7N9, as well as medium alone and ConA as positive control. The number of spots in the 
wells stimulated with ConA was too numerous to count for all groups, and so the results were 
set to a default of 500 spots/well (this is in accordance with the protocol developed for the 
ELISpot reader). A further examination showed that targeting with XCL1 activated the 
highest number of IFNγ-secreting cells for all stimulants, including stimulation with HAs 
from PR8, Cal07, H5N1, H7N9, and medium alone. However, responses after stimulation 
with HA from PR8 and Cal07 were higher than the other, indicating that these could represent 
reliable data. The number of activated IFNγ-expressing cells with XCL1 was not significantly 
higher for the PR8- or Cal07-stimulated cells, than the negative control cells.  
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Figure 3.11. Activation of IFNγ-secreting cells following vaccination with MIP1α-HA1, XCL1-
HA1, and αNIP-HA1: ELISpot measuring IFNγ-secreting cells was performed on splenocytes 
collected 4 weeks after i.d. vaccination. Splenocytes were stimulated with recombinant HA from PR8, 
Cal07, H5N1 and H7N9 as indicated.  
 
 
3.5 Mosaic vaccine constructs provide protection against viral 
challenge with influenza 
 
 
The ultimate testing of vaccine efficacy, is to examine vaccine-conferred protection against 
influenza. Thus, influenza challenge was performed with a lethal dose of either A/Puerto 
Rico/8/1934 or A/H1N1/California/07/09, as described in the methods chapter (section 2.5.4). 
 
3.5.1 Viral challenge in mice following intradermal delivery of HA1 
 
Mice that had received i.d. injection of the various plasmids encoding HA1 were challenged 
with a lethal dose of PR8 4 weeks after vaccination. Weight loss and survival proportions for 
each vaccine construct during the next 11 days is shown in figure 3.12. Results show that 
mice receiveing saline or αMHCII-HA1 had to be euthanized by day 8. Mice vaccinated with 
αMHCII-HAPR8 (positive control) showed only a minor reduction in weight before restoring 
their initial start weight. Mice vaccinated with the remaining constructs, αNIP-HA1, MIP1α-
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HA1 and XCL1-HA1, showed a similar weight loss for the first 6 days. The αNIP-HA1-and 
MIP1α-HA1-vaccinated mice then gained weight until about 95% of total body weight was 
restored. The XCL1-HA1-vaccinated mice had a slightly faster weight gain and restored their 
weight 100% by day 11. The positive control group was the only group where all mice 
survived. The survival proportions were higher for the MIP1α-HA1-vaccinated mice (85%) 
than for mice vaccinated with XCL1-HA1 (50%) and αNIP-HA1 (50%) (fig. 3.12). The 
survival proportions of αMHCII-HA1-vaccinated mice were similar to the negative control 
group.  
 
 
Figure 3.12. Weight loss and survival proportions of mice vaccinated i.d. with HA1–encoding 
vaccine constructs: 36 mice vaccinated i.d. with HA1 was monitored during the 11 days following 
lethal challenge with PR8 for A) weight loss, and B) survival. Mice were euthanized when reaching 
the limit of >20% weight loss. 
 
3.5.2 Viral challenge in mice following intramuscular delivery of HA1 
 
Mice that had received i.m. vaccination with the various HA1-constructs were challenged with 
a lethal dose of Cal07 4 weeks after vaccination. Weight loss and survival proportions for 
each HA1 vaccine construct during the next 11 days is shown in figure 3.13. Mice that 
received saline had to be euthanized by day 8. The MIP1α-, XCL1-, and αNIP-targeted 
vaccines gave similar weight curves that eventually restored the initial weight of all mice in 
each group. Mice vaccinated with αMHCII-HAPR8 (positive control) lost more weight than the 
A B
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mosaic vaccine constructs, except for αMHCII-HA1. All mice vaccinated with either MIP1α-
HA1, XCL1-HA1, αNIP-HA1, or αMHCII-HAPR8 survived until the experiment was 
terminated at day 12. Only 1 of the mice vaccinated with αMHCII-HA1 survived until day 12.  
 
Figure 3.13. Weight loss and survival proportions of mice vaccinated i.m. with HA1-encoding 
vaccine constructs: 36 mice vaccinated i.m. with the various plasmids encoding HA1 was monitored 
during the 11 days after lethal challenge with Cal07 for A) weight loss, and B) survival. Mice were 
euthanized when reaching the limit of >20% weight loss.  
 
3.5.3 Viral challenge in mice following intradermal delivery of HA1-17 
 
Mice that had received i.d. vaccination with the HA1-17 encoding vaccine constructs were 
challenged with a lethal dose of PR8 8 weeks after vaccination. The mice had then been 
vaccinated twice, and were challenged 4 weeks after the second dose. Weight loss and 
survival proportions for each HA1-17 vaccine construct during the next 13 days is shown in 
figure 3.14. Mice that received saline had to be euthanized by day 8. Mice vaccinated with 
αMHCII-HAPR8 were completely protected against the lethal dose of PR8. MIP1α-HA1-17, 
XCL1-HA1-17 and αMHCII-HA1-17 all had comparable weight curves. The weight curve of the 
αNIP-HA1-vaccinated mice shows a more rapid weight loss than with any other group, and 
only one of them survived until day 13. All mice in the positive control group survived, in 
consistence with previous experiments with this vaccine construct (Grødeland 2013). Of the 
remaining groups, the MIP1α-targeting induced the highest survival rate, followed by 
targeting with αMHCII, and then XCL1.  
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Figure 3.14: Weight loss and survival proportions of mice vaccinated i.d. with HA1-17-encoding 
vaccine constructs: 36 mice were injected twice (week 0 and 4) i.d. with the indicated vaccine 
constructs encoding HA1-17, followed by a lethal challenge with influenza PR8 at week 8. The mice 
were then monitored for 13 days after the challenge with PR8 for A) weight loss, and B) survival. 
Mice were euthanized when reaching the limit of >20% weight loss.  
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4 Discussion  
 
 
As presented in aims of study in section 1.4, there is a need for novel influenza vaccines that 
can confer a broader protection against influenza. In this study we have constructed novel 
mosaic hemagglutinin genes that were used as antigenic unit in APC-targeted vaccine 
proteins, delivered as DNA. We demonstrated efficient secretion of the constructs, and 
examined vaccine induced immune responses in mice. Importantly, mice immunized with 
mosaic HA were protected against a lethal challenge with influenza. This chapter will discuss 
the findings and methods applied in this work, and lastly the future prospects.  
 
 
4.1 Methodological conciderations  
 
 
4.1.1 Generation of mosaic antigens  
 
The parameters in the Mosaic Vaccine Designer tool can be set to a wide variety of settings 
and in that way generate a wide variety of mosaics from the same input set. We decided in 
this study to generate 1 peptide that represented all uploaded sequences. Previous studies 
employing the mosaic vaccine designer has shown that coverage (the mean fraction of 
natural-sequence k-mers included in the antigen, averaged over the set of natural sequences) is 
increased with increasing numbers of peptides in the antigen cocktail. One example is the 
generation of a mosaic cocktail for use as antigen in a novel vaccine against HIV[69]. Despite 
demonstrating a higher coverage using more peptides, the study also showed an increased 
coverage compared to a natural sequence, a conserved sequence, and a consensus sequence, 
when applying a single mosaic peptide[66].  
 
The aim of the present project was to generate a novel vaccine efficient at induction of 
cellular responses. The basis when epitope length was chosen, is that epitopes of CD8 T cells 
are continuous and typically 9 amino acids long. The mosaics generated in previous studies 
with HIV also utilized 9-mers[66, 69]. We therefore generated and scored mosaics based on 
the coverage of stretches of 9 contiguous amino acids in an attempt to stimulate cytotoxic T 
cells. Peptides binding MHC class II molecules, that are presented to CD4 T cells, display a 
great variability in length, ranging from 9-22 aa. Therefore, epitopes included in the mosaics 
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might in some instances also match the length of natural CD4 T cell epitopes. In a recent 
attempt to create a broader protective vaccine against influenza, an H5 mosaic was generated, 
setting the epitope length to 12 aa[2]. Here, they aimed at capturing CD4 epitopes, and induce 
antibodies that could cross-react within H5 strains of influenza. The vaccine generated 
showed an ability to confer broad protection against heterologous H5 influenza strains.  
 
A higher amount of input sequences will on a general basis lead to a better coverage of T cell 
epitopes. Still, the number of input sequences for generation of the HA1 mosaic was only 18. 
We ended up with this number after several attempts with larger input sets that all resulted in 
generation of a sequence with similar counterparts in nature. We reasoned that this could be 
due to an uneven representation of particular clusters, where the high degree of almost 
identical sequences present in the input would have an undue influence on the generated 
mosaic sequence. Thus, we constructed a tree, and selected evolutionary diverse strains as 
input.  
 
For construction of the HA1-17 mosaic, we used the same approach as for HA1. For several 
subtypes of influenza, such as H1 and H5, there are substantially more sequences available, as 
compared with other subtypes. The inclusion of all available sequences would therefore have 
biased the mosaic HA in favour of these well-characterized subtypes at the expense of others. 
Thus, we made evolutionary trees of well-described subtypes, and selected the more 
evolutionary diverse sequences as input sequences. For subtypes where less sequences are 
available, all were used as input sequences.  
 
Due to the low number of sequences, the rare threshold was set to 1, meaning every 9-mer 
present in the set of input sequences counts in the score. This was done because it was 
impossible for the algorithm to generate recombinant sequences with such a small input set 
without including the rare 9-mers. We tried using a higher rare threshold, but did not manage 
to get a resulting sequence from these attempts. A higher threshold might have lead to a more 
optimal mosaic, as the rarest 9-mers would not have been counted in the score. Although, in 
this particular case, a low rare threshold might not have meant that much, as the sequences in 
the input set are very diverse. Alternatively, we could have made a mosaic that was based on 
fewer subgroups, in order to have a larger input set and still an even distribution of the 
subgroups.  
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4.1.2 Cloning of mosaic HA encoding vaccine molecules  
 
The pLNOH2 vector was used as expression vector due to its ability to provide efficient 
uptake and secretion of Vaccibodies encoding different targeting units as well as antigens 
from different viruses and cancer models[51, 80]. It was originally designed for efficient 
production of Ig heavy chains, and therefore contains a VH leader sequence, followed by two 
cassettes for cloning of VH and CH regions. The pLNOH2 vector has a CMV promoter 
upstream of the V cassette, where the targeting units are cloned in. The antigenic units are 
cloned into the C cassette together with the dimerization unit (fig. 4.1). In this study, two 
mosaic HA sequences were both inserted into four different Vaccibody plasmids, each 
plasmid containing a specific targeting unit. The vaccine plasmids were transiently transfected 
into 293E cells, and ELISA analysis of supernatants demonstrated secretion of the vaccibody 
proteins.  
 
 
 
Figure 4.1. Gene construct encoding a vaccibody: The targeting unit (MIP1α, XCL1, αMHCII or 
αNIP) is inserted into the V cassette of the pLNOH2 vector.  An antigenic unit (mosaic gene) is 
inserted into the C cassette, next to the dimerization unit, which is composed of a shortened Ig hinge 
(h1 and h4 hinge exons) and a CH3 domain of human IgG[81]. Figure adapted from Fredriksen 
(Fredriksen 2006).  
 
 
4.1.3 Detection of antibodies in sera  
 
Inactivated influenza PR8, recombinant H1 from Cal07, and recombinant H5 from H5N1 was 
used as coat in the enzyme-linked immunosorbent assay (ELISA) for measurement of 
antibodies against these different HAs. The vaccine-encoded mosaic HA should be the only 
influenza antigen that the vaccinated mice could have been exposed to. The negative control 
	  68	  
groups, vaccinated with NaCl, remained negative for serum antibodies specific for any of the 
HAs throughout the experiments. Although ELISA measurements give quantitative 
information about antigen-specific antibodies in sera, they do not give information about 
these antibodies’ ability to confer protection against influenza. In order to test the neutralizing 
ability of the antibodies, a hemagglutinin-inhibition assay (HI-assay), or a neutralization 
assay, could have been performed. However, non-neutralizing antibodies can also provide 
protection against influenza by activating complement or by binding to Fc receptors on 
macrophages and NK cells. These antibodies may not be recognized by either HI-assays or 
neutralization assays, but will be readily detected in ELISAs.  
 
 
4.1.4 Measuring T cell activation  
 
The enzyme-linked immunosorbent spot (ELISpot) assay was used to measure T cell 
activation after vaccination. The assay measures the frequency of cytokine-producing cells at 
a single cell level. In this study, we demonstrated increased IFNγ secretion following in vitro 
re-stimulation of splenocytes with recombinant HA from PR8, Cal07, H5N1, and H7N9. The 
splenocytes were harvested from mice vaccinated with the different vaccines encoding the 
HA1 mosaic. Instead of complete HA proteins, we could have used individual peptides for 
stimulation of T cell responses. The use of peptides has both advantages and disadvantages. 
The particular peptide used will have a known binding preference for either MHC class I or 
class II molecules, thereby giving information about which T cells are activated. However, the 
selected peptide may not represent all epitopes, and may therefore give an incomplete 
detection of T cell activation.  
 
 
4.1.5 Mice as an animal model for evaluation of influenza vaccines 
 
Both ferrets and mice have played a central role in the development of vaccines and 
therapeutic drugs against influenza, and are still used in efforts towards the development of 
improved or even ”universal” vaccines. Other animal models are available that can be used to 
better address the immunobiology of virus infection and the development of disease 
intervention strategies. These include: other rodents (guinea pig, hedgehog, hamster, and 
cotton rat), birds, swine, nonhuman primates (rhesus macaques, cynomolgus macaques, 
squirrel monkeys and others), and even humans[82]. In this study, in vivo experiments were 
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carried out in female BALB/c mice, a laboratory bred strain of albino mice that has proven 
useful for a variety of immunological studies. Also, the αMHCII-targeting unit used in some 
of the vaccine constructs is specific for the MHC class II molecules in BALB/c mice (I-Ed). 
The small size of mice, and the husbandry practice for mouse colonies, make them an 
affordable choice for animal model in influenza studies. One of their weaknesses, is that most 
influenza viruses do not naturally cause disease in mice[82]. Also, there are several metabolic, 
anatomic, and cellular differences between humans and mice, compared to the differences 
between a human and e.g. a rhesus macaque. A positive result in mice does therefore not 
necessarily mean a positive result in humans, but gives an important indication as to whether 
a vaccine is functional. Also, testing of a vaccine in mice never give a false positive – if it 
does not work in mice, it will not work in humans. 
 
Mice are not natural hosts for influenza, but can nevertheless catch the disease if infected with 
some highly pathogenic viruses. The viral strains used for laboratory research typically have 
to be adapted to mice through serial passages. PR8 is an example of such a mouse-adapted 
strain, and has in the process lost the ability to infect humans. The virus is avirulent and can 
be administered intranasally in high doses[83]. Thus, it represents a safe animal model for 
influenza. Furthermore, it is easy to assess disease in infected animals. The clinical signs in 
mice include hunched posture, ruffled fur, weight loss, hind-limp paralysis, and death. Of 
these, weight loss can be more objectively assessed, and an ethically endpoint can be set well 
before the mouse dies. Here, we have used an endpoint of 20%. The relevance of weightloss 
as an indicator of disease has previously been verified by RT-PCR of viral loads in nasal 
washes, and by HE stainings of lung tissues harvested after viral challenge (Grødeland et al 
2013[79]).  
 
 
 
4.2 General discussion  
 
 
4.2.1 Structure of the vaccine proteins  
 
Sandwich ELISA assessed efficient secretion of the vaccine proteins. Previously, the targeting 
units of the vaccine proteins have been demonstrated functional by FACS analysis by binding 
to splenocytes or transfected cells (Grødeland et al 2013 [71]. However, the structural 
integrity of mosaic HA may only be assessed indirectly. Antibodies against HA (PR8 and 
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Cal07) failed to recognice mosaic HA antigens, and there are no available antibodies specific 
for the novel proteins that we have developed. In an attempt to visualize the vaccine proteins 
using SDS-PAGE and western blotting, an antibody specific for the dimerization domain of 
vaccibodies (HP6017-bio) was applied. Different conditions were used, including different 
gels (tris-glycine, bis-tris-glycine) and different gel concentrations (4-12%, 10%, 12%). 
Supernatants were up-concentrated prior to SDS-PAGE, in order to increase protein 
concentration. However, we were not able to obtain a functional western blot. We suggest that 
the concentration of the vaccine proteins in transfected 293E cells was too low for detection 
in the blot. Nevertheless, the vaccine proteins encoding mosaic HA protected mice against 
influenza challenges, and as such should bear structurally intact relevant antigenic structures.  
 
 
4.2.2 Targeting units  
 
Many molecules on APCs could be of interest for targeted vaccine delivery. In this study, we 
used targeting units that were already present in Bogen lab, and that previously had been 
shown to efficiently enhance immune responses. The chemokines MIP1α and XCL1 are 
efficient recruiters of leukocytes, and may activate these cells to enhance the local 
inflammatory response. The co-expression of chemokines with antigen has previously been 
observed to increase immune responses[84, 85]. The chemokine MIP1α binds the chemokine 
receptors CCR1, CCR3, and CCR5, which are members of the CC chemokine receptor 
family. The chemokine XCL1 mediates its chemotactic function by binding the chemokine 
receptor Xcr1, which is the only member of the C subfamily of chemokine receptors.  
 
An scFv was applied for targeting of MHC class II molecules that are expressed on 
professional APCs and thymic epithelial cells. MCH class II molecules bind peptides from 
internalized pathogens and present them to CD4 T cells, which subsequently activate antibody 
production by B cells. Targeting with αMHCII has previously been shown to induce complete 
protection against influenza[79]. An scFv encoding the hapten NIP was utilized as a non-
targeted control, and is of identical size and antigenic content as the scFv targeted to MHC 
class II molecules. 
 
The efficacy of a single immunization with influenza HA targeted to MHC class II molecules, 
chemokine receptors (CCR) 1, 3, and 5, and Xcr1 has previously been evaluated[71, 79, 86]. 
All three targeting approaches induced HA-specific immune responses, and protected mice 
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against a lethal challenge with influenza virus, in contrast to a non-targeted control[71]. They 
did however, induce qualitatively different immune responses. One of the studies showed that 
targeting to MHC class II molecules predominantly induced an antibody/TH2 response, 
whereas targeting to CCR1/3/5 or Xcr1 predominantly induced a CD8+/TH1 T cell 
response[71]. This indicated that there is a receptor-dependent polarization of immune 
reactions towards either TH1 or TH2, indicating that we can tailor vaccines into giving a 
desired immune response against a pathogen[52]. Based on this, MIP1α and XCL1 seem 
logical choices for targeting of the mosaic antigens, which were designed to activate T cell 
responses. In order to compare the CD8+/TH1 targeting strategy with the antibody/TH2 
strategy, we employed αMHCII as a targeting unit as well.  
 
4.2.3 Immune responses against HA  
 
The ELISA assays performed for measurement of induced antibodies, and the ELISpot for 
detection of activated T cells, tells us about the amount of induced immune responses, but not 
about how functional they are in preventing influenza. 
 
The findings of Grødeland et.al. (Grødeland 2015) demonstrated that targeting to Xcr1 leads 
to a low induction of IgG1 and a high induction of IgG2a. Targeting with MIP1α induces a 
similar result, and targeting with αMHCII induces clearly more IgG1 than IgG2. Targeting 
with the chemokines MIP1α or XCL1 will lead to activation of TH1 cells (and CD8 T cells), 
while targeting with αMHCII will lead to activation of TH2 cells. From theory, we know that 
a TH1 response is associated with the induction of IgG2a, IgG2b, and IgG3, and that TH2 is 
associated with the induction of IgG1[79, 87]. In this study, we detected antibodies using total 
IgG, meaning all different IgG isotypes will be detected. Therefore we can not say anything 
about the types of IgG induced. Serum antibodies against HA is a well-established correlate 
of protection against influenza[88, 89], and antibodies are the means of protection for the 
currently used inactivated trivalent influenza. Regarding activation of T cells, XCL1 and 
MIP1α have been demonstrated to be the most effective targeting units for induction of CD8 
T cell protection. This has been shown by depletion assays where CD8 T cells have been 
depleted and protection followingly abolished. Depletion of CD8 and CD4 T cells using using 
MHCII targeting, did however not abolish protection[71].  
 
Antigen targeting with MIP1α has previously been shown to induce both T cell responses and 
antibodies[52, 71]. Here, we found little antibodies when examining the induced responses 
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against PR8, but substantially more when examining antibody responses against HAs from 
Cal07 and H5. Interestingly, despite the very low amount of antibody responses detected 
against PR8, both MIP1α-HA1 and MIP1α-HA1-17 could provide protection in a viral 
challenge with PR8. In fact, when comparing to the other mosaic vaccines, targeting of 
mosaic HAs to chemokine receptors with MIP1α as targeting unit provided better protection 
against PR8 both in terms of reduced weight loss and survival proportions. These results 
indicate that MIP1α-targeting of the mosaics could induce both T cells and antibodies, which 
correlates with previous studies. Based on the findings of Grødeland et.al. (Grødeland 2015), 
we can assume that the induced antibodies are of the IgG2a isotype, due to activation of TH1 
helper cells. We did not test whether the activated T cells were CD4 T cells or CD8 T cells, 
but from previous studies, we know that antigenic peptides are presented on both class I and 
class II molecules when targeted with chemokines like MIP1α (or XCL1). We could have 
tested this by doing depletions of one of the T cell types. The dual presentation of mosaic 
antigen on the same APC has been described important for efficient activation of CD4 T 
helper cells that can augment the formation of cytotoxic T cells[54]. 
 
Targeting of antigen using XCL1 has been demonstrated to almost exclusively induce T cell 
responses[52]. This correlates well with the low titers of antibodies induced with the HA1 
mosaic vaccines against all three different HAs. An exception was the quite high titers against 
HA of Cal07 after intradermal vaccination, which might have contributed to the protection 
against Cal07. This might also explain why the observed protection was better against Cal07 
than PR8. In contrast to MIP1α-HA1, MIP1α-HA1-17 induced some antibodies against H5 and 
Cal07. However, based on previous results[86], we speculate that the observed protection 
against influenza challenges is due to the activation of T cells. XCL1 activated the highest 
amount of T cells in the ELISpot, which is in line with the findings of Fossum et.al. (Fossum 
2015); that targeting of the vaccines to Xcr1, predominantly leads to presentation on MHC 
class I molecules that interact with CD8 T cells. 
 
Targeting of the HA1 mosaic towards MHC class II molecules led to poor induction of 
antibodies following both intradermal and intramuscular vaccination. This is in contradiction 
with previous results from influenza vaccine experiments, which have shown that targeting 
with an scFv specific for MHC class II molecules can induce high titers of neutralizing 
antibodies against the HA antigen. Also, it is the only targeting unit able to mediate a 
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complete antibody-mediated protection against influenza (Grødeland et.al., 2013). In contrast, 
we here observed a complete lack of antibodies against all three viruses used in the ELISA 
assays. An explanation for this could be that the design of the mosaic HA (with 9-mers) have 
removed the relevant peptides that could be presented on MHC class II molecules for 
activation of CD4 helper cells, and the later activation of B and plasma cells. However, it can 
also not be ruled out that there is an undiscovered flaw in the particular MegaPrep used for 
vaccinations. An argument indicating this is the observed antibody responses after vaccination 
with aMHCII-HA1-17, as opposed to αMHCII-HA1. In correspondence with the lack of 
induced antibodies after vaccination with MHCII-HA1, this vaccine did not confer protection 
against PR8, and only one of the mice survived in the challenge with Cal07. Vaccination with 
αMHCII-HA1-17 did not induce production of antibodies against PR8, either, but induced 
antibodies against Cal07 and H5. In the challenge experiment with HA1-17, some protection 
against influenza PR8 was observed.  
 
In contrast to the challenge experiments with the HA1 mosaic, we saw a clear targeting effect 
in the experiment with the HA1-17 mosaic. All except one NIP-mice died, and the other three 
targeted mosaic vaccines, especially MIP-HA1-17, gave a higher survival and protection 
overall. Some targeting effect was seen in the challenge with PR8 and the HA1 mosaic, as 
MIP1α led to a higher survival rate than αNIP. XCL1 gave a similar survival rate as αNIP, 
but the XCL1 mice gained weight faster than the αNIP mice. Overall, MIP1α conferred the 
best protection against both PR8 and Cal07.	  
 
4.2.4 Why the mosaic approach give a broader protection  
 
 
The measured T cell and antibody responses, and the data from the viral challenges in this 
study, indicate a broader immunogenicity of the mosaic HAs as compared to a natural HA 
sequence. This is in line with previous studies[2, 69, 90]. One mechanism that might explain 
the breadth of protection, is that the 9-mer mosaics capture more T cell epitopes than a natural 
HA sequence. This could predominantly have led to a higher level of activated CD8 T cells, 
which epitope length are most commonly 9 amino acids long, but also to activation of CD4 T 
cells. Activation of CD4 T cells will have led to antibody responses broader than those 
inferred by a natural HA, through activation of B cells by TH1 helper cells. A second 
mechanism that might explain the breadth of protection, is that the mosaics have maintained 
an intact antigenic structure, and thereby its physiological function. Presumably, this will 
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make the mosaic proteins mimic natural processing, so that epitopes that stimulate T-cell 
responses in the vaccine will be the same epitopes that are processed and presented in natural 
influenza infection. Similarities between the virus and vaccine antigen processing could 
enhance the likelihood that the vaccine stimulates T cells that recognize virus epitopes 
presented by infected cells and that are not vaccine specific. Also, as the mosaics have a 
normal hemagglutinin function, they are presumably expressed as a cleavable protein. This 
might enable the stimulation of neutralizing antibody responses against the stem of HA. As 
our mosaics contain the most common stalk epitopes, the stem-specific antibodies could 
possibly be more cross-protective.  
 
4.2.5 Future prospectives  
 
 
Of the two mosaic antigens, the results with the HA1-17 mosaic was the most promising. HA1-17 
induced the overall highest antibody titers against the three HAs, and it also mediated the best 
protection against PR8. These results indicate that the HA1-17 mosaic is the most cross-
protective antigen of the two mosaics. Although it is the least similar sequence to PR8, it 
conferred a better protection than HA1 in the viral challenge. The challenge with HA1-17 also 
showed a clear targeting effect, where the non-targeted control was the least protective 
vaccine against PR8, as predicted from previous studies with vaccibodies. However, other 
immunological aspects of the vaccine constructs need to be further characterized. Conducting 
an ELISpot assay for the HA1-17 mosaic constructs will test the ability of the mosaic to 
activate T cells. For an assessment of T cell contributions to protection, a T cell depletion can 
be conducted, with depletion antibodies against CD8 T cells, CD4 T cells, or both. Cytokine 
profiles, antibody epitope coverage, and mapping, are other aspects that can be investigated in 
order to fully understand the mechanism responsible for protection. Furthermore, it would be 
interesting to create another HA1-17 mosaic with an epitope length set to 12 amino acids. This 
change in epitope length might increase the ability of the mosaic to capture CD4 T cells 
epitopes, and a comparison of induced antibody titers could be performed.  
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Appendix 1: Abbreviations  
 
 
 
aa   amino acids 
Ab  antibody 
APC   antigen presenting cell  
BCR   B- cell receptor 
BSA   bovine serum albumin 
Cal07   A/California/07/2009  
DNA   deoxyrinucleic acid 
ELISA  enzyme-linked immunosorbent assay 
ELISpot  enzyme-linked immunosorbent spot assay 
FCS   fetal calf serum 
HA   hemagglutinin 
HEK   human embryonic kidney 
HI   hemagglutinin inhibition  
HRP   horse radish peroxidase 
IFN   interferon  
Ig   immunoglobulin 
ITAM   immunoreceptor tyrosine-based activation motif 
MHC   major histocompatibility complex 
NA   neuraminidase 
NaCl   sodium chloride 
NIP   4-hydroxy-3-iodo-5-nitrophenylacetyl 
NP   nucleoprotein 
PAGE   polyacrylamide gel electrophoresis 
PAMP  pathogen-associated molecular patterns 
PBS   phosphate buffered saline 
PCR   poly chain reaction 
PR8   influenza A/PR8/8/34 (H1N1) 
PRR   pattern recognizing receptors 
PVDF   polyvinylidene fluoride 
RNA   ribonucleic acid 
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RPMI   Roswell Park Memorial Institute 
RT   room temperature 
scFv   single chain fragment variable 
SD   standard deviation 
SDS   sodium dodecyl sulphate 
SEM   standard deviation of mean 
SN   supernatant 
TAE   tris acetate EDTA buffer  
TCR   T cell receptor  
Th1   T helper 1 
Th2   T helper 2 
UV   ultraviolet  
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Appendix 2: Supplementary protocols 
 
 
 
Preparation of agarose gels:  
• Measure 1 g of agarose powder and add it to a microwaveable flask.  
• Add 50 ml of 1xTAE buffer and swirl the flask. 
• Heat the solution in a microwave for several short intervals until the agarose is 
dissolved – do not let the solution boil for longer periods as it may boil out of the 
flask.  
• Let the solution cool to about 50-55°C, swirling the flask occasionally. 
• Add 4 µl of a SYBR safe gel stain (ThermoFischer) that will bind to nucleic acids and 
allow the DNA to be visualized in ultraviolet (UV) light.  
• Pour the agarose solution into a casting tray and place a comb in the appropriate place.  
• Let the gel solidify in room temperature for 20-30 minutes.  
• Carefully pull out the comb and place the gel in the electrophoresis chamber (Bio-
Rad). 
• Add enough 1xTAE buffer to completely cover the gel.  
 
 
Procedure for agarose gel electrophoresis:  
• Add 4 µl of Sample Loading Buffer to each sample and mix.  
• Carefully pipette 20 µl of each sample into separate wells on the gel.  
• Pipette 10 µl of a 1 kb DNA ladder (BioNordika, NEB) and 10 µl of 100 bp DNA 
ladder (BioNordika, NEB) as molecular weight standards into a well each.  
• Run the gel at 100 V until dye has moved approximately 75-80% down the gel.  
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Preparing single-cell suspensions for ELISpot   
• Anaesthetize mice by i.p. injection of 150 µl ZRF and euthanize by cervical 
dislocation 
• Lay mice on dissecting board, ”left side” uppermost. 
• Surface-sterilize the skin using 70% ethanol. 
• Using sterile surgical instruments (scissors and forceps), cut through the skin just 
below the ribcage to visualize the spleen.  
• Remove the spleen with a smaller set of sterile instruments and trim away any fatty 
tissue.  
• Place spleen in a 15 ml tube containing RPMI medium with 10% FCS and 
supplements (ThermoFischer) and keep on ice for the whole procedure.  
• Sterilize a cell-dissociation sieve and a glass pestle with 70% alcohol. 
• Strain cells by pouring the spleen and medium through a sterile cell-strainer and into a 
Petri dish.   
• Press the spleen thorugh the strainer using the sterile glass pestle.   
• Transfer spleen cell suspension into 15 ml tube and keep on ice.  
• Repeat steps 1-4 for all tubes containing the harvested spleens.   
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Appendix 3: Recipes  
 
 
 
Buffers for ELISA assays:  
 
 
Blocking buffer                                                                                  300 ml 
                                                                                                     
30% BSA                                                                                              10 ml 
PBS azide (0,05%)                                                                              300 ml 
 
 
 
ELISA buffer                                                                                     500 ml 
                                                                                                     
30% BSA                                                                                           1,66 ml  
 Tween 20                                                                                              1,0 ml  
PBS azide (0,05%)                                                                           497,3 ml                 
 
 
 
Substrate buffer                                                                                 1 liter 
                                                                                                     
Diethanolamin                                                                                      97 ml 
dH2O                                                                                                   800 ml 
MgCl2 x 6 H2O (Mm = 203,3027 g/mol)                                           101 mg 
Azid (NaN2) (51,0032 g/mol)                                                             200 mg 
 
 
ELISA wash buffer                                                                        10 liters 
                                                                                                     
NaH2PO4xH2O (Mm = 119,9770 g/mol)                                             44,8 g 
Na2HPO4x12H2O (Mm = 141,9588 g/mol)                                       483,5 g 
NaCl  (Mm = 58,44 g/mol)                                                                2045 g 
Tween 20                                                                                            250 ml 
dH2O                                                                                                      10 L 
 
 
 
 
 
 
 
 
 
 
 
	   85	  
Appendix 4: Supplementary results, figures, 
and tables 
 
 
 
Mosaic hemagglutinin sequences (amino acids) 
 
 
HA1: 
 
DTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPLQLGKCNIAGW 
LLGNPECDLLLTANSWSYIIETSNSENGTCYPGEFIDYEELREQLSSVSSFERFEIFPKT 
SSWPNHETTKGVTAACSYSGASSFYRNLLWITKKGTSYPKLSKSYTNNKGKEVLVLWGVH 
HPPNIGDQRALYHTENAYVSVVSSHYSRRFTPEIAARPKVRGQAGRMNYYWTLLDQGDTI 
TFEATGNLIAPWYAFALSRGFGSGIITSNAPMDECDAKCQTPQGAINSSLPFQNVHPVTI 
GECPKYVKSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSG 
YAADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFLDIWT 
YNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDDECMESVK 
NGTYDYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSL 
 
 
 
HA1-17: 
 
DKICLGHHAVANGTKVNTLTERGVEVVNATETVERTNVPRICSKGKRTVDLGQCGLLGTL 
IGPPQCDQFLEFSADLIIERREGSDVCYPGKFTNEESLRQILRESGGIDKESMGFTYSGI 
RTNGATSACRRSGSSFYAEMKWLLSNSDNAAFPQMTKSYRNPRNKPALIIWGIHHSGSTT 
EQTKLYGSGNKLITVGSSKYQQSFTPSPGARPQVNGQSGRIDFHWLLLDPNDTVTFTFNG 
AFIAPDRASFFRGESLGVQSDVPLDSSCGGDCFHSGGTIVSSLPFQNIHPVTIGECPKYV 
KSDRLVLATGLRNVPQIESRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADKES 
TQKAIDGITNKVNSVIEKMNTQFTAVGKEFNNLERRIENLNKKMEDGFLDVWTYNAELLV 
LLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVKNGTYDYP 
KYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSL 
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Mosaic hemagglutinin sequences (nucleotides)  
 
HA1: 
 
GACACTATCTGCATTGGCTACCACGCCAACAATAGCACTGACACCGTGGATACCGTCCTG 
GAGAAGAACGTGACAGTCACTCACTCAGTGAACCTGCTGGAAGATAGCCATAATGGGAAA 
CTGTGCCTGCTGAAGGGAATCGCCCCTCTGCAGCTGGGCAAGTGCAACATTGCTGGCTGG 
CTGCTGGGGAATCCAGAGTGTGACCTGCTGCTGACCGCCAATTCATGGAGCTACATCATT 
GAGACTTCCAACTCTGAAAATGGAACCTGCTACCCAGGCGAGTTTATCGATTATGAGGAA 
CTGCGCGAACAGCTGAGCTCCGTGTCTAGTTTCGAGCGATTTGAAATTTTCCCAAAGACC 
TCAAGCTGGCCCAACCATGAGACCACAAAAGGAGTGACAGCCGCTTGTAGTTACTCAGGC 
GCCTCCTCTTTCTATAGGAATCTGCTGTGGATCACAAAGAAAGGCACTAGCTACCCCAAG 
CTGAGCAAATCCTATACCAACAATAAGGGCAAAGAGGTGCTGGTCCTGTGGGGAGTGCAC 
CATCCACCTAACATCGGAGACCAGCGCGCACTGTACCACACAGAGAATGCCTATGTCTCC 
GTGGTCAGTTCACATTACTCTCGGCGGTTCACCCCTGAAATTGCAGCACGACCAAAGGTG 
CGGGGCCAGGCCGGGCGGATGAACTACTATTGGACTCTGCTGGACCAGGGGGATACCATC 
ACATTCGAGGCTACCGGAAATCTGATTGCACCTTGGTATGCCTTTGCTCTGTCCAGAGGA 
TTCGGCTCTGGGATCATTACAAGTAACGCTCCAATGGACGAGTGCGATGCAAAGTGTCAG 
ACTCCCCAGGGCGCTATCAACAGCTCCCTGCCCTTTCAGAATGTGCACCCTGTCACCATT 
GGCGAGTGCCCCAAGTACGTGAAAAGCACCAAGCTGAGAATGGCAACAGGGCTGAGGAAC 
ATCCCTTCTATTCAGAGTAGAGGACTGTTTGGCGCAATCGCCGGCTTCATTGAGGGCGGG 
TGGACAGGGATGATCGACGGGTGGTACGGATATCACCATCAGAATGAACAAGGAAGTGGC 
TATGCTGCAGATCAGAAGTCTACACAGAACGCAATCAATGGAATTACTAACAAGGTCAAT 
TCCGTCATCGAGAAAATGAACACTCAGTTTACCGCCGTGGGCAAAGAATTCAATAAGCTG 
GAGAGGCGCATGGAAAACCTGAATAAGAAAGTGGACGATGGGTTTCTGGATATTTGGACC 
TACAACGCCGAGCTGCTGGTCCTGCTGGAGAATGAACGAACACTGGACTTCCACGATAGC 
AACGTGAAGAATCTGTATGAAAAGGTCAAAAGCCAGCTGAAAAACAATGCTAAGGAGATC 
GGGAACGGATGTTTCGAGTTCTACCATAAATGCGACGATGAGTGTATGGAATCCGTGAAG 
AACGGCACCTACGACTATCCCAAATATTCAGAGGAAAGCAAACTGAATCGCGAGAAGATC 
GATGGGGTGAAACTGGAATCCATGGGAGTCTACCAGATCCTGGCCATCTACTCTACAGTG  
GCTTCTAGTCTG 
 
 
HA1-17:  
 
GACAAAATCTGTCTGGGCCACCATGCTGTGGCAAACGGGACCAAGGTCAATACTCTGACC 
GAGCGCGGCGTGGAAGTGGTCAACGCCACAGAGACTGTGGAACGGACAAATGTCCCCAGA 
ATCTGCTCCAAGGGCAAACGGACCGTGGATCTGGGACAGTGTGGCCTGCTGGGGACACTG 
ATTGGGCCCCCTCAGTGCGACCAGTTCCTGGAGTTTAGTGCCGATCTGATCATTGAGCGG 
AGAGAAGGATCAGACGTGTGCTACCCTGGCAAGTTCACCAACGAGGAATCACTGCGACAG 
ATCCTGCGAGAGAGCGGAGGAATTGATAAGGAATCTATGGGGTTCACCTACAGTGGAATC 
CGCACTAATGGCGCAACCAGTGCCTGCAGGCGCTCAGGAAGCTCCTTCTATGCTGAGATG 
AAGTGGCTGCTGAGCAACTCCGACAATGCCGCTTTTCCTCAGATGACCAAATCTTACAGA 
AACCCTAGGAATAAGCCAGCACTGATCATTTGGGGGATCCACCATTCTGGAAGTACCACA 
GAGCAGACTAAACTGTACGGAAGCGGCAACAAGCTGATTACCGTGGGATCTAGTAAGTAT 
CAGCAGTCCTTCACACCATCTCCCGGCGCAAGACCACAGGTCAATGGACAGTCCGGCAGG 
ATCGACTTTCACTGGCTGCTGCTGGACCCAAACGATACCGTGACATTCACTTTTAATGGC 
GCTTTCATTGCACCCGATAGGGCTAGCTTCTTTCGAGGAGAGAGCCTGGGAGTGCAGTCC 
GACGTGCCACTGGATTCAAGCTGCGGAGGCGACTGTTTCCACTCCGGGGGAACTATCGTG 
TCCTCTCTGCCCTTTCAGAACATCCATCCTGTCACCATTGGGGAGTGTCCTAAGTACGTG 
AAATCTGATCGACTGGTCCTGGCCACAGGACTGCGCAATGTGCCACAGATCGAGAGCCGA 
GGACTGTTCGGAGCAATCGCTGGCTTTATTGAAGGCGGGTGGACTGGGATGATTGACGGC 
TGGTACGGGTATCACCATCAGAACGAGCAGGGGTCCGGATATGCAGCCGACAAGGAATCT 
ACACAGAAAGCAATCGATGGAATTACTAACAAAGTGAATAGCGTCATCGAGAAGATGAAT 
ACCCAGTTCACAGCCGTGGGGAAGGAGTTCAACAATCTGGAGCGACGGATTGAAAACCTG 
AATAAGAAAATGGAGGACGGCTTTCTGGACGTGTGGACATACAACGCCGAACTGCTGGTC 
CTGCTGGAGAATGAAAGAACTCTGGACTTCCACGATAGCAACGTGAAAAATCTGTATGAG 
AAGGTCAAATCCCAGCTGAAGAACAATGCTAAAGAGATCGGCAACGGGTGCTTCGAGTTC 
TACCATAAGTGCGACAACGAGTGTATGGAAAGCGTGAAAAATGGCACCTACGATTATCCC 
AAGTATTCAGAGGAAAGCAAGCTGAACAGGGAGAAAATTGATGGGGTGAAGCTGGAATCT 
ATGGGAGTCTACCAGATCCTGGCCATCTACAGTACAGTGGCTAGTTCACTG 
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Epitope coverage  
 
 
 
 
Supplementary figure 1. Epitope coverage of HA1-17 : The mean fraction of natural-sequence 9-mers 
shared with HA1-17 averaged over all sequences in the HA1-17 input set. Both exact matches (red), off-
by-one matches (orange) and off-by-2 matches (yellow) were included in the score. 
 
 
 
 
Supplementary figure 2: Epitope coverage of HA (PR8): The mean fraction of natural-sequence 9-
mers shared with H1 (PR8) averaged over all sequences in the HA1-17 input set. Both exact matches 
(red), off-by-one matches (orange) and off-by-2 matches (yellow) were included in the score. 
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Supplementary tables 
 
Supplementary table 1: Sequences selected for generation of the HA1-17 mosaic 
 
HA subtype Number of input  
sequences 
H1 18 
H2 9 
H3 9 
H4 8 
H5 8 
H6 8 
H7 12 
H8 1 
H9 9 
H10 8 
H11 8 
H12 1 
H13 2 
H14 2 
H15 3 
H16 5 
H17 2 
Total 112 
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Phylogenetic trees  
 
 
 
Supplementary figure 3: Phylogenetic tree of collected H1 sequences  
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Supplementary figure 4: Phylogenetic tree of collected H2 sequences  
 
 
 
 
 
 
 
Supplementary figure 5: Phylogenetic tree of collected H4 sequences  
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Supplementary figure 6: Phylogenetic tree of collected H6 sequences  
 
 
 
 
 
 
 
 
Supplementary figure 7: Phylogenetic tree of collected H7 sequences  
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Supplementary figure 8: Phylogenetic tree of collected H9 sequences  
 	  
